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ABSTRACT 
Effective primary and secondary prevention tools exist for cervical cancer in the form 
of human papillomavirus (HPV) vaccines and cervical screening. In order to maximize the 
impact of prevention strategies in Sweden and European countries, this thesis sought to 
investigate the long-term effectiveness of different screening strategies and the long-term 
risk associated with HPV infections, the organization and quality of existing screening 
programs, and the effectiveness of alternative vaccination strategies.   
HPV-based screening has been evaluated using intermediate outcomes while its 
effectiveness against cancer had not been fully examined. In Study I, the European 
randomized controlled trials (RCT) of screening methods were pooled to investigate the 
relative efficacy of HPV-based versus cytology-based screening for the prevention of 
invasive cervical cancer.  We found that HPV-based screening provides 60-70% greater 
protection against invasive cervical cancer compared to cytology-based screening.  
To address the issue of determining intervals for HPV-based screening and to 
investigate concerns regarding overdiagnosis with HPV-based screening, a long-term 
follow-up of the Swedescreen RCT was completed in Study II. The longitudinal 
performance of cytology- and HPV-based screening was explored and the sensitivity for 
cervical intraepithelial neoplasia grade 2 or worse (CIN2+) of HPV testing at 5 years of 
follow-up was similar to that of cytology testing at 3 years. Over 13 years of follow-up, we 
found that the increased sensitivity of HPV screening for CIN2+ reflects earlier diagnosis 
rather than overdiagnosis and low long-term risks among HPV negative women suggest 
that extending screening intervals with HPV-based screening would be possible.  
The incidence of low-grade cervical lesions is increasing in Sweden. Low-grade 
lesions require follow-up, creating a burden to the woman and the healthcare system. 
Examining the long-term HPV-type-specific risk for atypical squamous cells of 
undetermined significance (ASCUS), low grade squamous intraepithelial lesions (LSIL) 
and cervical intraepithelial neoplasia grade 1 (CIN1) is of interest to inform screening and 
vaccination programs. In Study III, we investigated the long-term type-specific absolute 
risk, population attributable proportion, and incidence rate ratios for ASCUS/LSIL by HPV 
type. The type-specific IRRs for ASCUS/LSIL were high in the first screening round but 
decreased over subsequent screening rounds. Type 16 contributed to the greatest proportion 
of low-grade lesions in the population followed by type 31. Most lesions were caused by 
new infections and found in the first screening round.  
Organized, population-based screening with quality assurance (QA) at all levels is 
recommended by the European Commission to ensure equity and cost-effectiveness of 
programs. Significant differences in cervical cancer incidence and mortality exist between 
European countries. In Study IV, a comprehensive questionnaire was developed and 
circulated among EU/EFTA countries to map current organization of programs and quality 
assurance efforts to understand prevention activities and inform future guidelines. The 
findings show that organized efforts for QA, monitoring and evaluation differed between 
and within countries, making it difficult to compare program effectiveness.  
HPV vaccination is underway in most European countries but efforts to organize and 
standardize vaccination program monitoring and evaluation are limited. Using the same 
questionnaire as in Study IV, we collected detailed information on HPV vaccination 
programs in EU/EFTA countries for Study V. Our findings suggest that the monitoring 
being performed varies across programs with regard to level of detail and the organization 
and quality of programs differ. There was a strong interest in the survey which affirms the 
significance of the issues addressed and the importance of continuing to evaluate program 
development and strengthen surveillance of vaccination program efforts.  
Since the introduction of HPV vaccination, vaccine prices have decreased 
significantly making upscaling of vaccination efforts more attractive. Specifically, 
questions have arisen regarding vaccination of older girls and extending the vaccination 
program to boys. Using a dynamic transmission model, in Study VI we compared different 
vaccination strategies and assessed the resilience of the vaccination program to a reduction 
in coverage. We found that vaccination strategies including an extended catch-up of women 
and introducing male vaccination may accelerate the prevalence reduction of vaccine HPV 
types among women. Further, including males in routine vaccination improved the 
resilience of vaccination programs.  
Taken together, the results of these studies seek to add evidence for the incremental 
optimization of prevention programs. The challenge will be translating research findings 
into practice and ensuring that programs have the tools they need to effectively monitor and 
evaluate changes.  
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1 INTRODUCTION 
Screening for cervical cancer was implemented before we knew what caused it. In the 
late 1920s, with a pioneering research spirit and somewhat unorthodox methods, Georgios 
Papanikolaou discovered that smears taken from the vaginal tract could be analyzed for 
cellular changes indicating cancer. Early epidemiological studies examining risk factors for 
female cancers found that cervical cancer incidence was much lower among nuns as 
compared to married women, suggesting that cervical cancer was caused by some aspect of 
the “coital experience” (1). Using, and further refining Dr. Papanikolaou’s “Pap” smear, 
cervical screening programs have been developed to identify abnormalities and remove 
them to prevent the development of invasive cancer. In the 1970s, Harald zur Hausen 
published a hypothesis proposing that human papillomavirus (HPV) could play a role in the 
development of cervical cancer (2), an etiological link he later demonstrated in the 1980s 
through identifying HPV types 16 and 18 in cervical cancers (3). HPV has since been 
categorized as a necessary, but not sufficient cause of cervical cancer and screening tests 
for the virus developed (4).  
Cervical screening exists to varying degrees in most high income countries and 
vaccination against HPV has been introduced in a variety of settings using a range of 
implementation schemes. With the implementation of cervical screening programs, cancer 
incidence has decreased and with the advent of HPV vaccination, protection against the 
most oncogenic HPV types is possible. We have made tremendous progress in 
understanding the etiology and natural history of cervical cancer. Now, we have a unique 
opportunity in front of us to maximize the potential of these prevention strategies. 
However, several questions remain – what screening tests and intervals should be used? 
What is the right balance of test effectiveness and acceptability while ensuring overall 
safety? How should programs be organized and what methods should be used to ensure 
their quality? What is the optimal target age(s) for HPV vaccination and should we extend 
vaccination to boys?  
This thesis seeks to address some of these remaining questions. The background 
section focuses on aspects of cervical cancer and HPV research that pertain to the work 
covered in this thesis, highlighting some of the complexities of this research field and 
providing context for the studies included. In the concluding thoughts, applications of the 
findings and future directions are considered.  
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2 BACKGROUND 
2.1 HUMAN PAPILLOMAVIRUS  
Currently, 202 human papillomavirus (HPV) types have been identified (5) with 2 more 
types under investigation, of which 40 are known to be sexually transmitted (6). The 
International Agency for Research on Cancer (IARC) has classified 13 of these types as 
oncogenic or high risk (HR) types (7). Types 16 and 18 are particularly notable in this group. 
They are responsible for approximately 70% of cervical cancer cases in the world (8), with 
some variation between regions. While less threatening from a cancer risk perspective, non-
high risk (non-HR) HPV types 6 and 11 cause approximately 90% of condyloma (genital 
warts) (9). Humans can be infected with one or multiple types at the same time. There is 
conflicting evidence on whether specific types tend to appear together (clustering) in multiple 
infections. While some evidence suggests that types do not appear more frequently together 
than they would have by chance (10, 11), other evidence suggests that there is clustering of 
types (12) and evidence for potential type-competition (13).  
HPV is the most common sexually transmitted infection (STI) and the risk of acquiring 
HPV from a first partner is high, especially if the partner is sexually experienced (14). The 
transmission probability of HPV 16 has been shown to be 40-60% per partnership (15, 16). In 
women without cervical abnormalities, worldwide prevalence of HPV is estimated to be 11-
12%, with a prevalence over 30% in the Caribbean and Eastern Africa and below 5% in 
Northern American and Western Asia (17). Prevalence usually peaks among 20-30 year olds, 
again with variation between regions and related, in part, to sexual behavior and screening 
availability (18). Worldwide, prevalence among women under 25 has been estimated to be 
24% and for women ages 25-34 prevalence was 14% according to a large meta-analysis of 
data on women without cervical abnormalities (19). Prevalence estimates for males come 
primarily from smaller cohort studies. Among young male Danish conscripts ages 18-29, 
prevalence was 34% (20). In the Human Papillomavirus in Men (HIM) Study prevalence was 
higher (36% to 51%), peaking again between ages 18-34 but with differences by sexual 
orientation (21).   
Unlike other STIs that are transmitted through bodily fluids, HPV is transmitted by skin 
to skin contact. Therefore, condoms can reduce the risk of transmission but do not fully 
prevent transmission (22). More recent studies examining oral prevalence of HPV suggest 
that HPV can be transmitted through oral-oral as well as oral-genital routes (23). Although 
rare, HPV can also be vertically transmitted from mother to child, with vaginal delivery being 
more risky than caesarean section (24). Risk factors for HPV are number of sexual partners, 
age at first intercourse, oral contraceptive use, infection with other STIs, immunosuppressive 
conditions (e.g. HIV), and smoking (25).  
Most HPV infections are transient with nearly 90% of infections clearing within 2 years 
(26) but type-specific clearance rates may differ, as demonstrated by Finnish modeling results 
(27, 28). The role that natural immunity may play in protecting individuals against reinfection 
with the same type has been difficult to study as separating new infections with the same type 
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from infections that are periodically undetectable is challenging from a methodological 
standpoint (29). However, evidence from a long-term follow-up of a Canadian cohort showed 
that detection of subsequent HPV infections of the same or a different type was associated 
with sexual activity, indicating that natural immunity did not provide protection against 
reinfection (29).  Those infections that persist carry a higher risk for developing into 
precancerous lesions or cancer (30, 31).  
Nearly all cervical cancer cases are caused by HPV. Evidence has accumulated rapidly 
in recent years suggesting a strong link between HPV and other anogenital cancers as well as 
certain oral pharyngeal cancers in the base of the tongue and tonsils. Recent estimates suggest 
that 88% of anal cancers are HPV positive (32), 50% of penile cancers, 43% of vulvar 
cancers, and 70% of vaginal cancers (17). Estimates for the proportion of cancers of the 
oropharynx that are HPV positive range from 17% to 56% depending on histology and region 
of the world (17).  
2.2 CERVICAL CANCER 
Cervical cancer is the third most common cancer among women worldwide and the 
second most common cancer among women of reproductive age in Europe (33). In the 
European region, an estimated 54,000 women are diagnosed with cervical cancer and 25,000 
women die from the disease each year (34). Country specific age-standardized incidence rates 
of cervical cancer vary across the European region from 2.1 to 23.9 per 100,000 women per 
year (34) and mortality rates vary from 1.1 to 13.7 (35). In Sweden, the age-standardized 
incidence of cervical cancer was 7.4 per 100,000 women per year with 452 new cases and 
178 deaths according to 2008 data (34). Incidence of cervical cancer in Sweden peaks around 
age 35 with a second peak at age 80 (36). Some evidence suggests that cancers appearing in 
the younger ages are more likely to be positive for a HR HPV type while cancers appearing 
among older women can be positive for non-HR types (37, 38). 
Squamous cell carcinoma (SCC) and adenocarcinoma represent the two most common 
histological types of cervical cancer. A nation-wide audit of cervical cancer cases in Sweden 
showed that 75% of cases were SCC and 20% were adenocarcinoma; other histological types 
including adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, and 
poorly differentiated histological types were much less common (39). Squamous cell 
carcinoma originates in the squamo-columnar junction, also known as the transformation 
zone, whereas adenocarcinoma originates in the glands of the cervix, higher up in the 
endocervical canal (Figure 1). FIGO (International Federation of Gynecology and 
Obstetrics) staging is used to classify the extent of tumor invasion. Staging at diagnosis is a 
significant predictor of cure prognosis (40).  
Precursor lesions have been identified and classified for squamous cell carcinoma and 
adenocarcinoma (to a somewhat lesser extent). Broadly, precursor lesions are identified first 
in cytology through cervical screening and divided into low- and high-grade lesions. Actual 
nomenclature used to categorize diagnoses differs across countries. High grade lesions are 
typically referred directly to colposcopy, a closer examination of the cervix, and biopsy to 
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determine need for treatment whereas low-grade lesions may be monitored with repeat-
testing either with cytology or HPV testing before referring to colposcopy.  
 
Figure 1. Anatomy of the female reproductive system and the cervix 
 
As lesion severity increases, the proportion of lesions that are HPV positive increases 
and the HPV types represented in the lesion change usually with a greater diversity of types 
in the low-grade lesions and a dominance of types 16 and 18 in higher grade lesions (41). 
Low-grade lesions are often considered to be just signs of an on-going HPV infection (41). 
High grade lesions are typically the result of a persistent HPV infection and can take several 
years to develop while invasive cancer is the result of a non-regressive lesion and can take 10 
years to develop (26). Lesions can regress but rates may differ by age and severity of lesion; 
higher grade lesions typically have a lower probability of regressing (26, 42). With regard to 
the effect of age, results from one modelling study show that 84% of lesions will regress in 
women under 34 compared to 40% in women over the age of 34 (43).   
Risk factors for cervical cancer are, in essence, the same as risk factors for contracting 
an HPV infection. Early age at sexual debut, as a proxy for first exposure to HPV, seems to 
have a particular impact on risk for cervical cancer (44). Other risk factors parallel risk 
factors for HPV infection and include: parity, lifetime number of sexual partners (45), 
smoking (46, 47) hormonal contraception (48), and infection with other sexually transmitted 
infections (49).  
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2.3 PREVENTION 
Efforts to prevent disease can be implemented at the primary, secondary, and tertiary 
levels. Primary prevention concerns itself with eliminating risk factors or increasing 
individuals’ resistance to disease before a disease can occur. Vaccination against HPV is an 
example of primary prevention for cervical cancer where vaccination reduces the likelihood 
that individuals will become infected with specific HR HPV types, in turn eliminating their 
risk for cervical pre-cancer and cancer associated with those vaccine types. Secondary 
prevention concerns itself with detecting disease in the preclinical phase before symptoms 
appear, and aims to treat early and reduce the chance that individuals experience lasting 
morbidity. Screening is a form of secondary prevention with the aim of early detection and 
treatment of cancer. Tertiary prevention is outside the scope of this thesis, but worth 
mentioning as it is what we seek to avoid through screening for early precursors: the 
treatment of clinical disease to prevent death or complications (50).  
With the advent of HPV vaccination, effective primary prevention of cervical cancer 
was made possible. Despite the progress with establishing vaccination programs and 
increasing vaccination coverage, secondary prevention through screening will remain 
relevant for several generations to come as non-vaccinated women age out of the screening 
ages and since the current vaccines do not include protection against all oncogenic types of 
HPV. Working towards integration of prevention activities will be critical.  
2.4 PRINCIPLES OF SCREENING  
By definition, screening is applied to a population and requires the testing of healthy 
(asymptomatic) individuals to identify those at risk for developing disease. Screening is:  
 
“The presumptive identification of unrecognized disease or defect by the application of 
tests, examinations or other procedures which can be applied rapidly. Screening tests 
sort out apparently well persons who probably have a disease from those who probably 
do not. A screening test is not intended to be diagnostic. Persons with positive or 
suspicious findings must be referred to their physicians for diagnosis and necessary 
treatment”  
- From the CC1 Conference on Preventive Aspects of Chronic Disease 1951, as quoted 
in the Wilson Criteria (51) 
  
In the late 1960s, Wilson and Jungner developed a comprehensive list of criteria for 
screening. These form the basis for evaluating screening methods and implementation and 
can serve as a guide when considering changes to existing screening efforts or introducing 
new programs.  
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   Table 1. Wilson Criteria for Screening (51) 
1 The condition sought should be an important health program 
2 
There should be an accepted treatment for patients with 
recognizable disease 
3 Facilities for diagnosis and treatment should be available 
4 There should be a recognizable latent or early symptomatic stage 
5 There should be a suitable test or examination 
6 The test should be acceptable to the population 
7 
The natural history of the condition, including development from 
latent to declared disease, should be adequately understood 
8 There should be an agreed policy on whom to treat as patients 
9 
The cost of case-finding (including diagnosis and treatment of 
patients diagnosed) should be economically balanced in relation to 
possible expenditure on medical care as a whole 
10 
Case-finding should be a continuing process and not a “once and 
for all” project. 
 
The Wilson criteria continue to be used and have been further expanded for evaluating the 
cost-effectiveness of screening (52).  
Cervical screening occurs to some extent in most high-income countries; however, the 
mode of implementation differs. Broadly, screening approaches can be divided into organized 
and opportunistic screening. Opportunistic cervical screening occurs in settings where 
screening facilities exist but women themselves must take the initiative to attend or may be 
reminded to attend by their primary care provider. In an organized screening setting, 
programs provide for a national or regional team responsible for implementation and require 
providers to follow guidelines, rules, or standard operating procedures. Organized programs 
define a quality assurance structure and mandate supervision and monitoring of the screening 
process. To evaluate impact, organized programs also require ascertainment of the population 
disease burden. Organized, population-based programs identify and personally invite each 
eligible person in the target population to attend a given round of screening (53).  Both 
organized and opportunistic screening can achieve cancer incidence reduction (54-56); 
however, organized screening programs have been more effective than opportunistic 
programs as they can reach a greater proportion of the target population and provide more 
equitable care (57). Furthermore, offering screening within the context of an organized 
program can achieve greater cost-effectiveness, encouraging tests that are taken at an 
appropriate interval to avoid overscreening and triage strategies that are applied effectively.  
European guidelines for quality assurance in cervical screening were first published in 
1993 and defined principles for organizing, monitoring, and ensuring quality of screening 
(58). Ten years later, a recommendation of the Council of the European Union prioritized the 
implementation of screening programs in EU member-states (59). In 2008, updated European 
guidelines for quality assurance in cervical screening were released to  reflect advances in 
screening technologies and prevention strategies (53).  Often, countries work with layers of 
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recommendations using national guidelines that build on international recommendations. The 
EU recommendations apply to all member states, but actual implementation is tailored to 
individual country settings and existing infrastructures.  
Simplistically, catching a cancer early can be viewed as a purely positive result of 
screening. However, trade-offs inherent in early diagnosis must be considered. Specifically, 
there is the risk of overdiagnosis, identifying a cancer that would have otherwise never 
progressed to being symptomatic or to cause death (60).  Usually this is the result of either the 
cancer regressing or growing so slowly that the individual dies of a competing cause (60). 
Overdiagnosis causes significant distress to the individual and potentially unnecessary 
procedures that can be invasive and incur lasting side effects, depending on the cancer type 
and available treatment options. It can be measured at the population level by examining the 
excess incidence with screening compared to the incidence in the absence of screening (61). 
In the context of cervical cancer, there has been an increasing concern about the 
overdiagnosis of precancerous lesions, lesions that would regress and never result in invasive 
cancer with switches to more sensitive testing methods such as HPV-based screening (62, 
63). This is of concern especially among women who want to have children and have been 
diagnosed with high grade precancerous lesions or early stage cancer. Studies have shown 
that treatment can increase the risk of miscarriage in the second trimester (64).    
2.5 SCREENING METHODS 
Screening methods should be evaluated based on their level of reliability and variation 
within the method and between observers. Furthermore, the choice of test should balance 
complexity and accuracy with speed and cost (51). There are a variety of cervical screening 
tests in use which require varying degrees of laboratory infrastructure and personnel skills to 
implement. The most common tests used in screening programs in high-resource settings are 
cervical cytology and HPV DNA testing. While cytological screening has reduced the 
incidence of cervical cancer, the sensitivity is moderate (between 50 – 75%) and can be 
variable depending on the quality of the sample taken and the sample reader (53, 65).  Given 
concerns about lower sensitivity with cytology-based screening and the etiological link 
between HPV and cervical cancer, HPV DNA detection as part of primary screening and/or 
triage has come into favor and has been implemented as a primary screening technique in 
some European countries (53, 65-68).   
Cervical cytology is based on the examination of exfoliated cells from the 
transformation zone of the cervix and excretions from the endocervical canal collected with a 
specially designed spatula or brush. This material can either be smeared and fixed directly 
onto a glass slide (conventional cytology) or released into a vial of fluid (liquid based 
cytology (LBC)). LBC samples are then filtered: the cellular material is fixed to a glass and 
interpreted and the liquid can be saved for further analysis, such as HPV DNA testing (69). 
Comparisons of conventional and liquid based cytology have shown that sample adequacy is 
often higher in LBC samples (70). This finding, coupled with the ability to reuse the sample 
for further analysis which eliminates the need to call the woman in for further testing has led 
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to a switch to LBC in many programs (71). Cervical cytology detects whether there is 
evidence of cellular changes indicating pre-cancer or cancer.  
HPV DNA testing employs the same sort of sample collection but the material is 
analyzed for presence of HPV DNA instead. Compared to cytology, HPV tests typically have 
better sensitivity but lower specificity when examining one round of testing. HPV DNA tests 
can be broadly categorized into methods in which the DNA is amplified (target amplification 
by polymerase chain reaction (PCR) or signal amplification such as in the hybrid capture 2 
test (HC2)) or non-amplified methods (which use nucleic acid probes). HPV tests can also be  
serology based. According to the Meijer Criteria, key requirements for a HPV test to be used 
as a primary screening test include high sensitivity and specificity and intra- and inter-
laboratory reproducibility (72). Evidence from European screening studies has shown that 
HC2 and GP5+/6+ PCR meet these requirements (73). The FDA approved the cobas HPV 
test which identifies types 16 and 18 separately and 12 other HR HPV types together for use 
as a primary screening test in 2014 (74).  
2.6 MEASURING SCREENING TEST PERFORMANCE  
Screening test performance can be measured by calculating the sensitivity, specificity, 
negative predictive value (NPV), and positive predictive value (PPV). These test 
characteristics are used to evaluate binary outcomes or continuous outcomes dichotomized at 
a meaningful cut-point and provide estimates of the test’s ability to identify positive and 
negative test results correctly against a gold standard or the true disease status. Sensitivity 
measures the ability of the test to correctly identify those who have the disease or condition of 
interest and is calculated as the number true positives detected by the test over the total 
number of true positives. Conversely, specificity measures the ability of the test to correctly 
identify those who are disease-free. It is calculated as the number of disease-free individuals 
correctly identified by the test divided by the total number of disease-free individuals. 
Sensitivity and specificity are measures of the test’s ability to correctly identify diseased and 
non-diseased individuals (50).  
Another important aspect of a test’s performance has to do with how predictive the test 
results are. In other words, if an individual tests positive, what is the probability that the 
individual is actually diseased and vice versa?  The NPV and PPV of a test give us a sense of 
how predictive the test is. The NPV is calculated by taking the number of correctly identified 
disease-free individuals and dividing by the total number of test-negatives identified (in other 
words, dividing by the sum of the true and false negatives). The PPV is calculated by taking 
the number of true positives identified by the test and dividing by the total number of 
positives identified by the test (50). The calculations are outlined in Figure 2.  
Ideally, screening tests would be able to perfectly discriminate between those with 
likely disease and those without; however, in reality this rarely happens. When evaluating a 
test’s performance, no single measure can be taken in isolation. For example, despite having a 
high sensitivity, a test can still have a low PPV which would cause many individuals to be 
false-positive and referred for further follow-up unnecessarily. If the follow-up for a test-
positive individual is invasive and runs the risk of significant side effects, then a low PPV 
  9 
would be particularly concerning. When making decisions about which test(s) to use and in 
what order, trade-offs must be considered and the test chosen should be a reflection of a 
carefully balancing costs, healthcare burden, burden to the patient, and efficiency.  
 
 Figure 2. Calculating sensitivity, specificity, NPV, and PPV 
Test results Truth or results of gold standard Total Calculations 
Positive Negative 
Positive True positives 
(TP) – diseased 
and tested 
positive 
False positives 
(FP) – disease-
free but tested 
positive 
Sum of all test-
positive 
(TP+FP) 
PPV = 
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
 
Negative False negatives 
(FN) – diseased 
but tested 
negative 
True negatives 
(TN) – disease-
free and tested 
negative 
Sum of all test-
negative 
(FN+TN) 
NPV =  
𝑇𝑁
𝐹𝑁 + 𝑇𝑁
 
Total Sum of all truly 
diseased 
(TP+FN) 
Sum of all truly 
disease-free 
(FP+TN) 
  
Calculations Sensitivity =  
 
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
 
 
Specificity =  
 
𝑇𝑁
𝐹𝑃 + 𝑇𝑁
 
  
 *Adapted from the Wilson criteria (51) and Gordis’ Epidemiology (50)   
 
So far, characteristics have been described as they are calculated with cross-sectional 
data referring to one visit – comparing one test with the “truth”, a gold standard test, or the 
comparison test of interest when both test results were temporally close together. In 
screening, we often want to know how tests perform over a longer period of time so that we 
can make decisions about the safety and effectiveness of different screening intervals with 
different tests. Thus, calculation of longitudinal test characteristics has been proposed as a 
key screening test performance indicator (75), more on this will follow in the methods 
section, under Study II. 
In the case of cervical cancer screening, cervical cytology has been used as the de facto 
gold standard, or comparison test when evaluating new screening methods. As such, issues of 
how good the gold standard truly is arise since cytology has not been studied in a randomized 
fashion and at this point, comparing cytology to no screening raises ethical concerns. The 
performance of cytology is a major point of discussion currently and at the heart of the 
analysis presented in Studies I and II.   
2.7 QUALITY ASSURANCE  
In order to achieve health gains, programs need to have systems and structures in place 
to be able to thoroughly evaluate whether the screening program is performing according to 
guidelines and is achieving the expected effect. Quality assurance consists of the management 
and coordination of the program throughout all levels of the screening process, invitations to 
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screening, testing, diagnosis, and follow-up of screen-test positives, to ensure that the 
program performs adequately and provides services that are effective and in-line with 
program standards (53). 
The European Guidelines for cervical screening outline specifics for designing, 
implementing, and monitoring the performance of programs. In the 2
nd
 edition of the 
guidelines, organization of screening, monitoring and evaluation, methods for diagnosis and 
treatment, and laboratory guidelines for cytology and histology are outlined. Instructions for 
carrying out audits of cervical cancer cases are included and point to the importance of 
evaluating both the process of screening – whether guidelines are being followed – as well as 
the impact of screening, are we preventing cases as we intended? Additionally, the guidelines 
provide suggestions for diagnosis terminology, methods for calculating key performance 
indicators. The guidelines introduce HPV testing as a primary screening method and mention 
vaccination as a new prevention tool. Taken together, the guidelines are detailed, specific, 
and comprehensive in their recommendations. They build on an extensive review of the 
literature and expert evaluation of existing evidence.  
Incremental revision of screening programs in the form of sequentially optimizing with 
new strategies is ideal as each change can be monitored and evaluated for logistical ease and 
health impact. As healthcare programs increasingly face budgetary trade-offs, evaluating 
strategies from a health economics perspective will be critical and evaluating new strategies 
in comparative health effectiveness studies could be a way forward.  
2.8 CERVICAL SCREENING IN SWEDEN 
Organized cervical screening began in the 1960s in Sweden and was nationwide by the 
1970s. Since 1998, women ages 23-50 have been invited to screening every 3 years and 
women ages 50-60 have been invited every 5 years, which translates into 12 screening tests 
per woman per lifetime. Invitations are sent once 3 or 5 years have passed since the last 
screening test recorded. Therefore, actual attendance is usually measured within 3.5 or 5.5 
years. If a woman does not attend following her invitation, a reminder is sent each year until 
she attends or actively opts out of the invitational system. Opportunistic tests, taken outside 
the organized program, are integrated into the call and recall system and delay the next 
organized invitation until the age-specific interval has passed with the goal of reducing over-
screening, currently at  around 10%. In 2013, 69% of screening tests were taken within the 
organized screening program and the coverage was 80% for women ages 23-60 (76). 
In Sweden, we have seen a dramatic decrease in cervical cancer incidence and mortality 
since organized screening was introduced in the late 1960s. Following the introduction of 
screening, there was a significant increase in carcinoma in situ (CIS), a downstaging pattern 
that would be expected with the implementation of screening. In recent years the cervical 
cancer incidence has remained stable, with some increase in adenocarcinoma (Figure 3). This 
raises questions as to whether we have reached the performance plateau of cytology-based 
screening in Sweden. By switching to HPV-based screening, we could increase the sensitivity 
of screening. Cytological cervical screening has been shown to be more effective for the 
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prevention of SCC than adenocarcinoma, perhaps as a result of greater ease in sampling the 
squamo-columnar junction (77). 
 
Figure 3.  
 
That said, perhaps holding the incidence steady is a sign of continued screening progress 
given the increasing incidence of precancerous lesions in the population, especially among 
young women (76). One study has shown that in the absence of screening, the Nordic 
countries would be experiencing incidence rates on par with high incidence rates in low-
income countries (78). 
National recommendations are proposed by the National Board of Health and Welfare 
(Socialstyrelsen) and then implemented at the regional level. Screening is carried out by 
midwives at maternity care centers. There are some variations in invitation procedures and 
age-ranges. The intent with the current guidelines was to invite and test every woman up to 
and including age sixty, but in many regions this was interpreted as no invitations or testing 
after age sixty. Therefore, many women were not tested after the age of fifty five, and many 
of the oldest women were never invited. For women entering the screening ages, the first 
invitation to screening is either sent the year the woman turns 23 which results in some 22 
year olds being screened or once the woman turns 23.  
The Swedish program is monitored and evaluated at both the national and regional 
levels. All regions report individual-level screening data to the Swedish National Cervical 
Screening Registry, described in more detail in the methods section (Nationellt 
Kvalitetsregister för Cervixcancerprevention, NKCx). The NKCx evaluates the overall effect 
of the screening program and a process register, Cytburken, evaluates whether screening is 
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carried out according to the guidelines. Changes to the existing guidelines are made by the 
National Taskforce for Cervical Cancer Prevention (Nationella Arbetsgruppen för 
Cervixcancerprevention, NACx), at the request of the national collaboration of Regional 
Cancer Centers.  Initiatives from professional organizations have also helped shape screening 
in Sweden. The expert group of the Swedish Society of Obstetrics and Gynecology (Svensk 
Förening för Obstetrik och Gynekologi, SFOG) issued national guidelines for the 
management of screening test results in 2010. Laboratories are evaluated externally by 
quality assurance organizations. Regional steering groups in conjunction with region cancer 
centers are responsible for quality assurance, follow-up, and changes to the system. The 
steering groups consist of the head of the invitation system, the head of cytology, a maternity 
care physician or the coordinating midwife, an oncologist, and an STI expert is recommended 
in some instances.  
Cervical cytology is currently used as the primary test (LBC is used in 20 of the 21 
regions) but the decision to switch to primary HPV-based screening was made in the fall of 
2014 and a recommendation has been drafted and released for commenting by the National 
Board of Health and Welfare. A final recommendation is expected this summer, 2015. The 
proposed intervals, tests, and age-ranges are as follows:  
 
Table 2. Proposed screening schedule for primary HPV-based screening  
Sweden (52) 
Age-range Test Interval 
23-29 Cytology 3 years 
30-49 HPV DNA test 3 years 
50-64 HPV DNA test 7 years 
 
The proposed screening schedule will not, in its current form, reduce the number of screening 
tests over a lifetime. Instead, by switching to a more sensitive test in the ages 30-49 and 
extending the upper-age limit, we can strengthen the screening program’s effect and further 
reduce incidence of invasive cancer. Keeping cytology testing for the first three screening 
tests among women ages 23-29 reflects a desire to avoid overdiagnosis, given the high 
prevalence of HPV in this age-group. Using HPV DNA testing as the primary screening test 
means that cytology will be used as the reflex test. Women who are found to be HPV-positive 
above the age of 30 will be triaged with cytology and referred to colposcopy if cytological 
abnormalities are found. Since the first vaccinated cohorts will be entering the screening ages 
soon, further adjustments may be needed as this current proposal does not officially take into 
account vaccination status and testing methods and intervals could be adjusted.  
2.9 HPV VACCINATION 
Two prophylactic vaccines for HPV have been developed and registered with the 
European Medicines Agency (EMA): Cervarix
TM
, a bivalent vaccine protecting against HPV 
types 16 and 18 developed by GlaxoSmithKline and Gardasil
TM
, a quadrivalent vaccine 
protecting against HPV types 6, 11, 16, and 18 developed by Merck. The quadrivalent 
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vaccine was available on the Swedish market in the fall of 2006 and the bivalent vaccine 
came a year later. In HPV-negative women, the bivalent and quadrivalent vaccines have been 
shown to have a 99% and 100% efficacy against HPV 16 and 18 CIN2 or CIN2+, 
respectively and 65% (bivalent) and 43% (quadrivalent) efficacy against CIN2+ irrespective 
of HPV type (28).  
A 9-valent prophylactic HPV vaccine, developed by Merck, was approved by the U.S. 
Food and Drug Administration in December 2014 and a positive opinion on recommending it 
for authorization was released by the EMA in March of 2015 (79). Compared to the 
quadrivalent vaccine, the antibody responses achieved with the 9-valent vaccine for types 6, 
11, 16, and 18 were non-inferior compared to the quadrivalent vaccine. For HPV types 31, 
33, 45, 52, and 58, the efficacy against high-grade cervical, vaginal, and vulvar lesions in the 
per-protocol population of the vaccine trial was 96.7% (80).  
Efficacy from the trials provide an estimate of the vaccine impact in an ideal setting; 
since implementation of vaccination in population, further studies have examined vaccine 
effectiveness (81). Studies examining vaccine effectiveness against early HPV-disease 
endpoints have reported decreases in condyloma incidence (82, 83) and a herd protection 
effect for heterosexual males when females are vaccinated (84). More recently, effectiveness 
against cervical abnormalities has been shown (85). Reported adverse events following 
vaccination have been mainly mild in nature, namely swelling and pain at the injection site 
and fever (86, 87). Population-based safety studies examining the vaccines have shown them 
to be well-tolerated with no evidence to support an association between quadrivalent HPV 
vaccination and autoimmune, neurological, and venous thromboembolic events (88) and no 
evidence of an association between quadrivalent HPV and multiple sclerosis or other 
demyelinating diseases (89).  
The vaccines were originally recommended in 3-dose schedules given at 0, 2, and 6 
months for Gardasil and 0, 1, 6 months for Cervarix. Following further immunogenicity 
studies, non-inferiority of 2-doses compared to 3-doses was demonstrated for young women 
(90). WHO has reviewed the existing evidence on dosing and they updated their 
recommendations in 2014, approving a 2-dose schedule for use in young girls (91). Using a 
2-dose schedule may reduce costs and logistical challenges of achieving high coverage, but 
will need to be monitored to ensure similar effect once implemented in population.  
Currently, the vaccination is recommended for women ages 9 or older. There is no 
upper age limit for the quadrivalent and bivalent vaccines as studies have shown efficacy 
through age 45 (92, 93). Vaccination of males is hotly debated, especially given that males 
are carriers of HPV and increasing evidence that males are at risk for a variety of HPV-
related cancers. Vaccination of both genders is implemented in a limited number of countries: 
Australia, Austria, Canada and the United States (94, 95).  
2.10 HPV VACCINATION IN SWEDEN 
The bivalent and quadrivalent vaccines were made available at a subsidized price for 
girls ages 13-17 in 2007. HPV vaccination was opportunistic, meaning that individuals had to 
seek and request vaccination at their primary care provider or a vaccination center until 2012 
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(96). The vaccination coverage achieved during the opportunistic period was approximately 
30%, on par with what has been seen with other non-organized HPV vaccination efforts (97). 
Organized, school-based vaccination began in 2012 targeting girls ages 11-12 with a catch-up 
of girls ages 13-18.  The age-range for vaccination in Sweden was chosen based on early 
modeling studies using HPV serology data (98).  
By 2014, ≥1 dose coverage was 82% for the first cohort of girls in the school-based 
program (born 1999-2001) and 59% for girls in the catch-up target ages (born 1993-1998) 
with variations between regions (99). Vaccination up to the age of 26 has been promoted in 
two regions of Sweden, Stockholm and Skåne. In Stockholm, the vaccine is free for this 
extended age-group and the coverage in 2014 was approximately 20%. Vaccination of boys 
is allowed in Sweden, but no organized efforts are in place to systematically invite or 
encourage vaccination among boys. In accordance with the new recommendations from the 
WHO, Sweden decided to switch to a 2-dose schedule for the routine school-based 
vaccination of young girls, effective January 2015 (91, 100).  
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3 AIMS 
Through epidemiological studies of cervical screening and incidence of precancerous 
cervical lesions and cervical cancer, an investigation of organization and quality assurance 
in screening and vaccination programs, and mathematical modeling comparing HPV 
vaccination scenarios, this thesis sought to inform optimization of cervical cancer 
prevention by means of screening and HPV vaccination. 
 
The specific aims of the studies are as follows: 
  
Paper 1: To obtain estimates of the relative eﬃcacy of HPV-based versus cytology-based 
screening using pooled data from four randomized trials; to determine how eﬃcacy 
changes according to age, cancer stage, and morphological features; and to estimate the 
duration of protection against cancer by screening method.  
 
Paper 2: To assess whether the increased sensitivity of screening with HPV-based testing 
may represent overdiagnosis and to compare the long-term duration of protective effect 
against CIN2+ in HPV- and cytology-based screening using data from the long-term 
follow-up of a randomized controlled trial of primary HPV screening. 
 
Paper 3: To evaluate the HPV type-specific long-term ARs, PARs, and IRRs for low-grade 
lesions, in the context of a population-based randomized controlled trial. Secondarily, to 
quantify whether surveillance bias caused by clinical intervention based on a type-restricted 
HPV test materially affected the risk estimates. 
 
Paper 4: To characterize current organization and quality assurance of screening programs 
in Europe and to estimate the financial resources required to monitor them using a 
questionnaire circulated to all EU/EFTA countries.  
  
Paper 5: To describe progress with implementing organized HPV vaccination programs in 
EU/EFTA countries and to investigate vaccination program monitoring and evaluation 
strategies and associated program costs.  
 
Paper 6: To compare the impact of different vaccination scenarios on HPV infection 
control among women and to assess the resilience of each vaccination strategy to a 
temporary reduction of coverage, using real-life data from the Swedish vaccination 
program. 
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5 MATERIALS AND METHODS 
5.1 CANCER AND INFECTIOUS DISEASE EPIDEMIOLOGY 
Epidemiology is “the study of the distribution and determinants of health-related states 
or events in specified populations, and the application of this study to control of health 
problems” (from J.M. Last as quoted in dos Santos, 1999 (101)). Epidemiologists are 
interested in what causes disease in a population and therefore they are equally concerned 
about those that develop disease and those that do not and what the potential differences may 
be. Using this information, prevention strategies can be developed to target specific risk 
factors and early markers of disease (50, 101).   
Cancer epidemiology, as a field of study, began developing in the mid-20
th
 century as 
deaths from infectious diseases declined in high-income countries. Noteworthy studies on the 
link between smoking and lung cancer and bladder cancer incidence in chemical industry 
workers influenced the development of exploring cancer etiology. Typically, cancer takes 
years to develop and occurs relatively infrequently in populations, making it logistically 
challenging to study: large study populations and extended follow-up time are required to 
observe outcomes. Cancer epidemiology usually includes not only the study of cancer itself, 
but also its precursors, and as such, it is also interested in the prevention of disease and 
identifying risk factors for developing disease (101).  
Infectious disease epidemiology concerns itself with the spread of infections through 
contact (direct and indirect), vectors, air, food and water and corresponding disease outcomes 
in changing populations of susceptible, immune, and recovered individuals. When studying 
infectious diseases, the likelihood of transmission, the severity of disease caused by the 
infection, the duration of the infectious period, and the level of immunity gained by having 
been exposed are some important determinants of estimating the impact of an infection in 
population (102). In 2008, approximately 2 million or 16.1% of all cancers in the world were 
attributable to infections, and of those 2 million cancers, 30% could be attributed to HPV 
(103).  
Cervical cancer research is uniquely positioned at the intersection of infectious disease 
and cancer epidemiology. When studying cervical cancer prevention, the hardest endpoint, 
and ultimate measure of impact of prevention efforts in population, is estimating reductions 
in invasive cancer incidence and mortality. Measuring HPV prevalence in population 
provides an early measure of primary prevention and can give us insight into the likelihood of 
eliminating HPV. Precursor lesions give us a sense of HPV prevalence in population and can 
be used to evaluate detection rates in screening and impact of vaccination. Estimating overall 
burden of disease – precursors and cancer – allows health systems to plan resource allocation 
and evaluate cost-effectiveness of prevention strategies.  
5.2 STUDY DESIGN 
A range of study designs have traditionally been used in epidemiological studies of 
cancer and applied according to the type of research question posed. Study designs are 
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broadly divided into observational (cohort, case-control, cross-sectional) and experimental 
studies (randomized controlled trials and quasi-experimental designs).  The main difference 
being that in the former, the researcher observes and reports on what occurs in a population 
but does not actively make changes and in the later, the researcher intervenes and then 
observes what happens as a result of the new treatment, screening method, vaccine etc. The 
data used in this thesis are primarily from randomized controlled trials (RCT), a study design 
that can be considered to be ideal for evaluating new interventions and their (potential) side 
effects (50).  
In a RCT, consenting study participants are randomly assigned to receive the new 
intervention or a control intervention and then followed for the outcome of interest. 
Typically, RCTs are blinded, meaning that information on who receives the new intervention 
is kept secret during the course of the study so as not to influence the behavior of the 
participants or the follow-up/care they receive in the study. RCTs can be double blinded, 
meaning that both those that are implementing the intervention and the participants 
themselves are unaware of the randomization status. In some instances, trials can even be 
triple blinded, in which case those analyzing the data receive coded information that does not 
reveal the randomization status.  
RCTs are uniquely positioned to provide information on whether the exposure 
(intervention) of interest is casually associated with the outcome. The randomization process 
aims to make the different analysis groups comparable with regard to both observable and 
non-observable factors aside from the intervention that may influence the outcome. By 
keeping the groups the same except for the intervention, the effects observed can be attributed 
to intervention, assuming that other potential sources of bias can be minimized. Results from 
RCTs are presented as comparisons between analysis groups, often referred to as the 
intervention and control groups.  
Not all interventions are well-suited for randomization. Withholding an intervention we 
know to be effective can be ethically difficult unless further evaluation of the intervention is 
justifiable; likewise, we cannot randomize individuals to an intervention or a lack of 
intervention that we know to be harmful. Ongoing monitoring of study results is critical to 
ensure that if the benefits or harms exceed expectations, we can adjust the study protocol 
accordingly or stop the intervention. We must weigh the risks and benefits associated with 
each intervention we want to evaluate and carefully select the study setting best suited for 
examining the intervention’s effects.  
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5.3 DATA SOURCES 
5.3.1 Overview of data sources and methods by study 
 
Population or 
Setting 
Material Method 
I Women attending 
organized cervical 
screening in 
England, Italy, the 
Netherlands, and 
Sweden 
Long-term follow-up of the European 
randomized controlled trials on primary HPV 
screening. Data from the ARTISTIC 
(England), NTCC (Italy), POBASCAM, (the 
Netherlands), and Swedescreen (Sweden) 
trials.  
 
Data linkage to NKCx for Swedescreen 
through July 2011 in Skåne, September 2011 
in Gothenburg; January 2012 in Stockholm, 
and March 2010 for all other regions.  
Kaplan Meier 
curves  
Cumulative 
incidence 
Detection rate ratios 
II Women ages 32-
38 attending 
organized cervical 
screening in 
Sweden 
Long-term follow-up of the Swedescreen 
trial. 
 
Data linkage to NKCx through September 
2011 for Gothenburg, Janaury 2012 for 
Stockholm, and December 2011 for all other 
regions. Baseline HPV information from both 
study arms used. HPV testing performed on 
frozen baseline samples from the control arm.  
Kaplan Meier 
curves 
Cumulative 
incidence 
Longitudinal test 
characteristics 
III Women ages 32-
38 attending 
organized cervical 
screening in 
Sweden 
Long-term follow-up of the Swedescreen 
trial. 
 
Data linkage to NKCx through December 
2012 for all regions. Baseline HPV 
information from both study arms used. 
HPV testing performed on frozen baseline 
samples from the control arm. 
Absolute risks 
Incidence rate ratios 
Population 
attributable 
proportions 
IV 29 EU/EFTA 
countries 
Survey data collected through the European 
Union survey on organization and quality 
control of cervical cancer screening and HPV 
vaccination programs 
Descriptive data on 
screening program 
organization and 
quality assurance 
V 27 EU/EFTA 
countries 
Survey data collected through the European 
Union survey on organization and quality 
control of cervical cancer screening and HPV 
vaccination programs 
Descriptive data on 
vaccination 
program 
organization and 
quality 
VI Swedish HPV 
vaccination 
program 
HPV prevalence (chlamydia screening 
program) 
Sexual behavior (Sex in Sweden) 
Fertility, mortality, and population data 
(SCB) 
Vaccination coverage 
(Folkhälsomyndigheten and personal 
communications) 
Percent reduction of 
HPV attributable to 
vaccination 
Relative cumulative 
number of vaccine 
doses 
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5.3.2 Registers and register linkages 
The Swedish national population-based registers enable much of the epidemiological 
research that is produced in Sweden and allow for unique, longitudinal and population-level 
studies of health conditions. There are registers that contain demographic information (held 
by Statistics Sweden) and registers that contain information related to health outcomes, 
prescriptions, and healthcare visits (held by the National Board of Health and Welfare).  In 
addition, there are quality registers that are used to monitor and evaluate specific health 
services and outcomes using clinical data, with the overall aim of improving healthcare 
provision and supporting research and healthcare management.  
Registers in Sweden contain individual-level data, identifiable and linkable through a 
personal identity number (104). Access to registry data varies by type of information included 
but for registries containing health information, access is strictly regulated by register holders 
and extracts are only granted after ethical review and proof of data protection measures. The 
Swedish healthcare system is tax-payer funded and offered in a largely decentralized manner 
where equal access to care and reasonable timeframes for receiving care are a priority. Health 
registers allow for administrative review of the quality and effects of healthcare services. This 
thesis makes use of RCT databases and three registers, as described below.  
 
The Personal Identity Number and data linkages 
 
Personal identity numbers (PIN) were introduced in 1947 and are given to all Swedish 
citizens and immigrants who become permanent residents or plan to reside in Sweden for 
more than one year. The number consists of 10 digits: six digits corresponding to the 
individual’s date of birth and then a four-digit identification number (the third digit shows the 
individual’s gender and the last digit is a control number).  The PIN is used in all aspects of 
civil life, vital statistics, and healthcare services to efficiently and accurately identify 
individuals (104). For research, the PIN enables correct assessment of the population size for 
calculating national statistics, and individual-level linkages between registers and between 
primary data collection and registers for research. It allows for the accurate longitudinal 
follow-up of individuals through changes in residence status, healthcare visits, and health 
outcomes.  The PIN is used to link data from different registers but then is removed before 
analysis and replaced with a study identification number to protect individual’s privacy.  
 
The Swedish National Cervical Screening Registry (Nationellt Kvalitetsregister för 
Cervixcancerprevention, NKCx) 
 
The Swedish National Cervical Screening Registry (NKCx) was started in 2002 with 
the aim of building an evidence-base for monitoring and evaluating cervical cancer 
prevention in Sweden. Data on all cytologies and histologies are included in the database with 
information dating back to the 1970s for some counties and complete information for all 
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counties since the early 1990s. Information on invitations to screening is included from the 
1990s and onwards (complete information after 2005). Data on HPV tests carried out either 
as primary screening or triage/test of cure are also collected. Laboratories and regional 
screening organizations export their data and send copies to the registry. The data are cleaned, 
standardized, and made available for research and program evaluation. Systematized 
nomenclature of medical diagnoses (SNOMED) coding according to the Swedish Society of 
Clinical Cytology is used by the registry to classify cytology and histology results. The codes 
that are approved for use in Sweden are shown in Table 3. CIN terminology is used for 
histological test results.  
 
Table 3. Swedish standard cytology nomenclature (Sverigeremissen), 2013 
Category Description SNOMED 
Sample quality 
Inadequate M09010 
Endocervical cells lacking M09019 
Normal Benign M00110 
Squamous cell 
diagnosis 
ASCUS M69710 
Mild dysplasia (CIN1/LSIL) M74006 
ASC-H M69719 
Moderate dysplasia (CIN2) M74007 
Severe dysplasia (CIN3) M80702 
Squamous cell carcinoma M80703 
Glandular epithelial 
cells 
AGUS M69720 
Adenocarcinoma/AIS M81403 
Uncertain/other cell 
type 
Atypia in cells of uncertain origin M69700 
Malignant neoplasm of uncertain origin M80009 
 
The registry is led by a steering group of experts from different disciplines within cervical 
cancer prevention. Reports are produced each year that provide information and feedback on 
data completeness and key quality indicators (76).  
 
The Swedish Cancer Register (SCR) 
 
The Swedish Cancer Register was started in 1958 and is held by the National Board of 
Health and Welfare. It covers the whole population and reporting of malignancies is 
mandatory; reports from all examinations (clinical-, morphological -, and other laboratory 
examinations) must be sent. The six regional cancer registries, within the regional cancer 
centers, are responsible for the initial cleaning and checking of the data submitted. Data are 
then compiled at the national level in the Swedish Cancer Registry, containing detailed 
information on the cancer, its diagnosis, and the reporting entity. Information on staging has 
been systematically included since 2004. The completeness of the registry was evaluated in 
1998 by comparing cancer cases reported to the cancer registry with those reported to the 
Hospital Discharge Registry. Underreporting of cancers was found to be age-dependent with 
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more underreporting in older ages for women. The underreporting of female genital cancers 
was found to be low (3.4%) (105).  
 
The Swedish Total Population Register (TPR)  
 
Records of the Swedish population have been kept since the 1600s, when church 
parishes started to keep track of their members. The system was computerized in the 1960s 
and later transferred to the tax authority in 1991. Demographic information including births, 
deaths, civil status, place of residence, immigration, and emigration are reported by local tax 
authorities and compiled by the national tax authority. Such information is then reported to 
the Total Population Register, complete since 1968 and held by Statistics Sweden (Statistiska 
Centralbyrån, SCB) (106).  
 
Swedescreen  
 
Data for the first three studies of this thesis come from the Swedecreen trial, which was 
started in 1997 as the Swedish randomized controlled trial of primary HPV-based screening. 
A total of 12,527 consenting women, aged 32-38, attending population-based invitational 
screening in Sweden were randomized 1:1 to HPV test and cytology (intervention arm) or 
cytology only with samples frozen for future HPV DNA analysis (control arm). The 
randomization was performed independently by the Cancer Registry of Stockholm using 
computer-generated numbers. Women were recruited between May 1997 and November 
2000 in Göteborg, Malmö, Stockholm, Umeå, and Uppsala. Inclusion criteria were simple, 
women needed to consent to participate in the study. No exclusions were made based on 
previous screening status or history. HPV-positive women were invited for a second HPV test 
at least one year later and women with type-specific persistent infections were then invited to 
colposcopy. A similar number of random double-blinded procedures were performed in the 
control arm to address possible ascertainment bias (107). Women are followed with 
comprehensive registry-based follow-up. The primary outcome was the relative rates of CIN 
grade 2 or worse (CIN2/CIN3+) found in subsequent screening. Secondary outcomes were 
the relative rates of CIN2/CIN3+ found in baseline screening and outcomes stratified by 
grade of CIN (CIN2 or CIN3+). The study was unblinded in August 2003 and women were 
informed of their HPV results because the proportion of women who were HPV positive and 
found to have a CIN2+ lesion was greater than expected (108).  
The Swedescreen study data contain all the original information collected at baseline 
for the study participants and the interventions conducted, including follow-up HPV test 
results and results of the study colposcopies.  A long-term follow-up of the cohort has been 
completed with individual linkage to NKCx. This long-term follow-up includes all cytology 
and histology test results for the cohort. Raw cytology and histology diagnoses were cleaned 
using the Swedescreen SNOMED code translation table, which was updated and expanded 
for the studies in this thesis. In 2012, HPV testing of the frozen baseline samples in the 
control arm of the trial was completed. This information is available in the long-term follow-
  23 
up data. Additional censoring information (death or migration status) was collected from 
Statistics Sweden and used in Study I. Information on cancer cases during follow-up is also 
included.  
 
Other primary HPV-screening RCTs in Europe 
 
Closely following the Swedescreen trial, primary HPV screening trials were started in 
other European countries to compare the effectiveness of HPV- to cytology-based screening 
with precursor lesions as an endpoint: the ARTISTIC (A Randomized Trial In Screening To 
Improve Cytology) trial in England (2001), the New Technologies for Cervical Cancer 
screening (NTCC) trial in Italy (2002), and the Population-Based Screening Study 
Amsterdam (POBASCAM) trial in the Netherlands (1999). All studies recruited from routine 
screening within organized, population-based screening programs. The age-ranges differed 
somewhat, reflecting country-specific screening differences and a desire to examine HPV-
based screening in different age groups: ages 20-64 in ARTISTIC, 25-60 in NTCC, and 29-
61 in POBASCAM. In NTCC and POBASCAM women were randomized 1:1 as in 
Swedescreen to HPV (intervention) and cytology (control arm) testing, whereas in 
ARTISTIC, women were randomized 3:1. Individual, study-specific analyses have been 
published explaining the studies and baseline data, risk for precursor lesions, and, more 
recently, longer-term follow-up of study results (66, 108-113).   
5.4 STATISTICAL METHODS  
5.4.1 Study I 
As the European primary HPV screening trials were not separately powered to look at 
cancer as an outcome, in order to be able to study the screening test effect on invasive 
cervical cancer, data from the ARTISTIC, NTCC, POBASCAM, and Swedescreen were 
pooled. This study was a joint effort within the EU FP7 project, PREHDICT. Data were 
collected and in each country and prepared for pooling according preset definitions. For 
Sweden, cases were identified through linkages to the pathology data in NKCx and the SCR. 
The diagnostic slides for these cases were collected from biobanks and were then reviewed 
by an expert pathologist (WR).  Of the 23 potential cases identified, 20 were reviewed by the 
pathologist (the remaining 3 were found only in pathology registry or only in cancer registry 
and considered not confirmed). Twelve cases were confirmed as invasive cervical carcinoma 
at the specimen’s blind re-review and included as cases in the pooled analysis. Cases were 
further classified by morphological features (squamous cell carcinoma, adenocarcinoma, and 
adenosquamous) and FIGO stage (1A vs >1A). Baseline information on HPV status was 
obtained from the original data and follow-up tests were obtained through linkage to the 
NKCx for all cytological and histological results (follow-up through July 2011 in Skåne, 
September 2011 in Göteborg, January 2012 in Stockholm, and March 2010 for all other 
regions).   
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The data were analyzed by intention to screen – analyses were conducted according to 
study arm and person-time counted from recruitment until the end of follow-up, cancer 
detection, death, or migration, whichever came first. Invasive cervical cancer is most often 
symptomatic meaning that diagnosis is not necessarily screening-dependent.  Person time was 
counted until the end of the registry linkage when no case or migration/death was observed. 
This is dissimilar to how follow-up time was counted in Studies II and III where precursor 
lesions, which are most often asymptomatic and are detected through screening, were used as 
the outcome and last date of screening was used as the end of follow-up for individuals who 
did not experience a lesion.  
Cumulative incidence of cervical cancer by study arm and then by baseline test result 
status (HPV negative in the intervention arm and cytology negative in the control arm) was 
calculated using the Kaplan-Meier (KM) method. All studies except ARTISTIC used a 1:1 
randomization to study arms. Since ARTISTIC used a 3:1 randomization, the results of the 
crude KM could be biased. An adjustment was made by multiplying the intervention arm 
women at risk and cases by 0.5 and the control arm by 1.5. Study-adjusted detection rate 
ratios were calculated for invasive cervical cancer in the intervention versus the control arm. 
Rate ratios were calculated for the overall observation period, and then for the first 2.5 years 
of follow-up accounting for the prevalence screen and the period thereafter, separately. 
Further analyses included calculating rate ratios for women with a negative test at entry, and 
by morphology, stage, age at enrolment, and proportion of women with at least 1 biopsy 
result to explore the extent of diagnostic procedures. 
Given that the study design and implementation were somewhat different across the 
trials included, heterogeneity was assessed. Heterogeneity arises when there is between-study 
variation in the study results that is greater than what could be expected by chance (114). For 
this analysis, heterogeneity was assessed with a χ2 test and the I2 statistic. The χ2 provides a 
statistical test of homogeneity which is specific but not always sensitive, meaning that large 
p-values do not necessarily mean that heterogeneity can be ignored (115). Therefore, the I
2 
statistic can be useful as it shows the proportion of the variance in the effect estimates that is 
due to heterogeneity between the studies included in the pooled analysis (0% means 
variability is due to sampling errors in the studies and not heterogeneity between studies and 
100% means the variability is due entirely to heterogeneity between the studies) (114). The 
main results of the analysis were generated from fixed-effects models which assume that each 
of the studies estimate similar exposure effects but as a further check, random effects models 
were run as well where the exposure effects were allowed to vary between studies (115).  
5.4.2 Study II 
This long-term follow-up of the Swedescreen trial made use of both study arms and the 
updated HPV testing in the control arm. Baseline test results were categorized as HR HPV 
positive, HR HPV negative, cytology negative (normal), and cytology positive (ASCUS or 
worse). Analyses were completed by baseline test result and study arm. Women with 
unsatisfactory baseline cytology or missing baseline cytology were excluded when examining 
cytologies; women with unknown HPV baseline result were excluded for the HPV analyses; 
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and women with both unknown HPV and an unknown cytology result were excluded in the 
cytology and HPV analyses. Follow-up began at the first study test result (HPV or cytology at 
baseline) and ended at the first histologically confirmed CIN2+ or CIN3+ lesion, the last 
registered sampling date, or 13 years of follow-up, whichever came first. The last registered 
sampling date was used as the end of follow-up for individuals who did not experience an 
outcome since high-grade lesions are typically screen-detected and we wanted to include only 
observation time when outcome status was known. Information on cytologies and histologies 
was obtained through linkage to the NKCx with follow-up through September 2011 for 
Göteborg, January 2012 for Stockholm, and December 2011 for all other regions.  
Cumulative incidence by study arm and baseline test result were calculated as 1 minus 
the Kaplan Meier curve (the complement of the negative predictive value, cNPV). 
Longitudinal test characteristics, sensitivity specificity, positive predictive value (PPV), and 
negative predictive value (NPV), were calculated adjusting for censoring as a measure of how 
well a baseline test result can predict future occurrence of disease. Typically, test 
characteristics are calculated and compared to a gold standard at the same point in time. In 
this case, we measured the gold standard (a histologically confirmed high-grade lesion) 
during follow-up which complicates matters as the women included at baseline were not 
necessarily followed for the entire period of interest. Therefore, the numerator and 
denominator must be upweighted as if the censored women were still at risk using the 
censoring distribution estimated from the Kaplan Meier curve. Conditional weighting was 
used to reflect that censoring may depend on the baseline test result (116). We calculated test 
characteristics at 3, 5, 8, and 10 years of follow-up to reflect existing and proposed screening 
intervals. A two sample test of proportions was used to assess sensitivity of cytology in the 
control arm at 3 years (the recommended interval) compared to sensitivity of HPV testing in 
the intervention arm at 3, 5, 8, and 10 years. Overdiagnosis was assessed visually and by 
overall counts of outcomes in the control and intervention arms. The concern has been that 
HPV testing results in overdiagnosis; therefore, for there to be no evidence of overdiagnosis, 
the number of cases in the control arm should catch-up with the number in the intervention 
arm over long-term follow-up (60). 
5.4.3 Study III 
Data from both arms of the Swedescreen trial were used in this analysis along with the 
updated HPV testing in the control arm. The updates to the testing method used in the control 
arm allowed for typing of non-HR HPV types as well. Individuals were followed from their 
first study test results (HPV or cytology) until the first study diagnosis of an ASCUS, LSIL 
(cytology), or CIN1 (histology) diagnosis depending on the analysis or the last registered 
cytology, if no outcome was observed. Women who were diagnosed with a CIN2+ lesion 
before a low-grade lesion were censored with the assumption that treatment for the CIN2+ 
lesion would have changed the course of their disease history. Information on disease 
outcomes and screening episodes were obtained through a linkage to the NKCx, with a 
country-wide linkage through December 2012.  
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To explore the HPV type-specific risk for low-grade lesions, a series of estimates were 
calculated. Type-specific cumulative incidences (absolute risks, AR) were calculated at 14-
years of following using 1-Kaplan Meier curve to account for censoring given the extended 
follow-up time. Absolute risks give a measure of the risk that a woman testing positive for a 
specific HPV type will develop the disease of interest in the time specified. This measure is 
useful for making clinical predictions but, unadjusted ARs do not provide evidence for 
whether that infection caused the lesion.  
Unadjusted and adjusted incidence rate ratios (IRR) were calculated to provide an 
estimate of how much the risk of low-grade lesions is increased among women positive for a 
specific HPV type compared to women negative for that time in a particular timeframe and 
how much this increase is actually caused by the type-specific infection after adjusting for co-
infections. The IRRs were calculated using Poisson regression and adjustment for co-
infections was handled by entering individual type information into the model. Follow-up 
time was used as the timescale and entered as a covariate in the models. We measured 
follow-up time as time-since-entry into the study; this was chosen since HPV status was 
measured at entry into the study and follow-up time gave a measurement of time since HPV 
status was known. A Wald test was used to test whether the IRR for each type was different 
than that of the IRR for type 16.  
The population attributable proportion (PAR) was calculated to estimate the proportion 
of disease that would be eliminated if the infection was prevented in the population. This 
measure is of particular interest now that we have highly efficacious vaccines that can 
prevent infection with specific types. Estimating the PAR gives us a sense of what we can 
expect from the vaccine in terms of impact on low-grade lesions. Type-specific PARs were 
calculated for the first screening round in the study as the adjusted IRR minus 1, divided by 
the IRR and multiplied by the proportion exposed in the population (117, 118). The estimates 
were run separately for each study arm and then combined, adjusting for study arm in the 
model.  
5.4.4 Study VI 
Mathematical models are equational representations of complex occurrences that help 
us to study systems. In healthcare research, models allow us to make inferences about the 
future based on available data and give us an opportunity to simulate potential interventions 
and their impact on health outcomes. Infectious disease modeling seeks to represent the 
dynamics of an infectious agent as well as the spread of it in the population (the transmission 
between individuals). It can be further extended to investigate control measures, such as 
vaccination (102). Substantial modeling work is currently being done on HPV and HPV-
related diseases since the advent of HPV vaccination and a desire to further evaluate 
prevention strategies. Models differ quite significantly, not only in the modeling approach but 
also with regard to how the input data are defined and which assumptions are made. 
Methodological choices in modeling are extensive and require a deep knowledge of the 
infectious agent in question and its sequelae. The ability of a model to represent reality is 
often influenced by the quality and detail of existing data sources and assumptions about 
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uncertainties in the natural history and spread of the disease. The elegance of modeling is 
finding a parsimonious but valid representation of the system’s complexity.  
The model used in this thesis was developed by Dr. Iacopo Baussano at the 
International Agency for Research on Cancer building on work completed in transmission 
modeling at Imperial College London in the group of Dr. Geoffrey Garnett. Further 
development is ongoing with the model, but to date, it has been used to explore transmission, 
clearance, and persistence of HPV as well as upscaling or extending  HPV programs in other 
settings (15, 119, 120). Model validation against Swedish and Italian data has been performed 
(121). The model is a population-based age-structured transmission dynamic model, 
accounting for men and women that are susceptible, infected, and immune to HPV infection. 
Age-structuring the model allows parameter estimates and rates within the model to vary by 
age. Movement between states (susceptible, infected, and immune) in a dynamic model is 
based on rates.  
For Study VI, we chose HPV prevalence as the outcome of interest because changes in 
prevalence would be the earliest impact of the vaccination program. Input data were Sweden-
specific and were collected and prepared for modeling calculations. HPV prevalence data 
were obtained from the chlamydia screening program in Southern Sweden (Skåne) (122). 
Information on sexual behavior was taken from the Sex in Sweden survey, conducted in the 
late 1990s and one of the most comprehensive data sources on sexual behavior of both men 
and women (123). The raw data from Sex in Sweden was kindly provided by Professor Bo 
Lewin at Uppsala University. The average number of new partners in the past 12 months was 
extracted and the proportion of the population in low, middle, and high sexual activity classes 
was estimated. We assumed vaccine efficacy according to data from the vaccine trials (28). 
The aim of the study was to compare the impact of alternative HPV vaccination 
strategies and assess vaccination program resilience to a reduction in coverage. Using 
vaccination coverage data from the Swedish program, 3 alternative scenarios based on a 2-
dose vaccination schedule were designed to represent possible expansions of the program and 
are described in more detail in the main findings section. Resilience of the vaccination 
program was explored by modeling a 5-year, 50% decrease in vaccination coverage and then 
comparing vaccination scenarios. Drops in vaccination coverage can be caused by changes in 
healthcare priorities or political will behind a vaccination program, public mistrust in a 
vaccine, etc. and have lasting effects on disease outcomes. Mitigating the negative effects of a 
decrease in coverage is of interest to ensure robust health programs that can withstand 
temporary changes.  
For each scenario proposed, we explored the percent relative reduction in prevalence of 
vaccine targeted HPV types (RAV) among women ages 15-35 and then by birth cohort. 
Vaccine types 16 and 18, targeted by the bivalent and quadrivalent vaccines were evaluated 
in the main analysis and vaccine types 16, 18, 31, 33, 45, 52 and 58 (9-valent vaccine) were 
included in supplementary analyses. We further calculated the absolute gain in prevalence 
reduction, calculated as the % RAV of the 3 alternative scenarios as compared to the base 
case (the current vaccination program). Resilience over time of the vaccination program was 
calculated as the % RAV estimated with and without the temporary coverage reduction. 
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Finally, we estimate the cumulative number of doses in each alternative vaccination strategy 
and compared that to the base-case to provide a comparison of health resources needed under 
potential expansions of the program.  
5.5 SURVEY METHODS 
5.5.1 Studies IV and V 
While screening exists to a degree in European countries, the organization of screening 
efforts and the extent to which screening is monitored and evaluated differs. The European 
Centers for Disease Prevention and Control guidelines for HPV vaccination have encouraged 
monitoring of vaccination programs. Vaccination efforts differ across Europe as well with 
regard to level of organization and monitoring and evaluation capabilities.  In Studies IV and 
V, we sought to map the current organization and quality of screening and vaccination 
programs.  
The questionnaire tool was designed after a review of existing EU guidelines, country-
specific guidelines and protocols, and published literature on quality assurance and 
organization. A draft of the survey was circulated among program experts in England, 
Finland, Norway, and Sweden for feedback on the readability and content of the survey. The 
questionnaire was also sent to the Screening Quality Assurance Group at IARC for 
commenting. Feedback was received from England, Norway, Sweden and IARC and 
incorporated. The full questionnaire has been included in as an Appendix but briefly, the 
survey included seven main sections, of which four addressed screening and the remaining 3 
collected information on vaccination.  
The questionnaire was sent, in Word doc form, to ministries of health, key screening 
program administrators and/or researchers associated with the programs in all 34 EU 
(including separate surveys sent to England, Northern Ireland, Scotland, and Wales) and 
European Free Trade Agreement (EFTA) countries. If no response was received, a follow-up 
email was sent and then new contacts were found. Given the length of the questionnaire and 
the level of detail requested, we encouraged countries to divide up their responses between 
departments if needed or work as a team to fill in the questionnaire, sending updated versions 
when they could. Countries were asked to submit supporting information where possible – 
standard operating procedures, reports, and guidelines.  
Data collection started in May 2012 and continued until March 2014, when the last 
response was received. Collecting information proved to be challenging as finding 
individuals willing and able to respond, especially in countries were programs were less 
defined, was difficult. The filled-in questionnaires and corresponding documents sent by 
countries were collected into country-specific folders and entered into a Masterfile. The level 
of detail submitted by countries and consistency in answering questions varied significantly. 
For publication, the results were analyzed and compiled separately for screening and 
vaccination programs. Further reflections on the content and process are included in the 
methodological considerations section.  
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6 ETHICAL CONSIDERATIONS 
Studies I, II, and III are all based on the long-term follow-up of the Swedescreen trial 
and data from ARTISTIC, NTCC, and POBASCAM were used in Study I. When the 
Swedescreen trial was started in 1997, the women received information on the trial, the study 
tests, and follow-up procedures as part of the oral and written consent process. The 
information highlighted that women could withdraw at any point and offered contact 
information for questions. The study was granted approval in 1996 by the ethical review 
board. We requested a new ethical approval for the long-term follow-up of Swedescreen 
including a new registry linkage, identification of cancer cases, data sharing, and testing of 
baseline samples in the control arm. As no further study tests were carried out in the long-
term follow-up, there was no risk for physical pain or discomfort. We reasoned that 
conducting HPV testing of samples in the control arm 15 years after the samples were taken 
made re-contacting the women logistically difficult and less relevant since HPV infections 
typically clear on their own. Furthermore, all women consented to HPV testing and continued 
to be invited to routine screening following their inclusion in the study, minimizing the risk 
for missing a diagnosis. Ethical approval was obtained for the other European trials and all 
women provided informed consent.  
The content of the data collected in Studies IV and V should be a matter of public 
record in participating countries as the information collected had to do with healthcare 
systems and funding sources. We applied for ethical approval for the questionnaire and 
received an advisory opinion (rådgivande yttrande). The advisory opinion stated that the 
study did not fall under the auspices of an ethical review, in part because the data were not 
personal.  In writing the ethical approval, the main issue of concern we weighed was that of 
the political implications for individuals reporting controversial data for their country (e.g. 
programs were not operating in-line with guidelines). We chose to present results at the 
country level, mentioning only generally the affiliation of the responder(s) in an effort to 
protect the individual responder but also allow for opening a dialogue around how 
programs compare and can be improved. Since public health practice dictates that it is 
ethically questionable to engage individuals in prevention programs that do not achieve 
their goals, the act of sharing information on program performance, while perhaps 
detrimental to the image of the country program, is an ethical obligation. 
No new data were collected for the mathematical modelling in Study VI. That said, 
ethical approval was still applied for and received. Data on sensitive issues is needed for 
transmission models of STIs – namely information on sexual behavior and HPV infection 
status. Information on sexual behavior from the Sex in Sweden survey was used in 
aggregate form and anonymized (no record exists linking those contacted with the survey 
responses). Similarly, only information on age and gender was known for the data used 
from the anonymous chlamydia screening program in Skåne, Sweden for HPV prevalence. 
Population level information was obtained from SCB and the National Board of Health and 
Welfare. The risk for individuals was minimal as all information was aggregated and then 
simulated and presented at a population level.  
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7 MAIN FINDINGS AND DISCUSSION 
7.1 STUDY I 
A total of 176,464 women were included, contributing 1,214,415 person-years over 
follow-up. The median follow-up time was 6.5 years (covering 2 screening rounds) and 107 
invasive cervical cancers were detected. The overall rate ratio (RR) for cervical cancer in the 
intervention arm compared to the control arm, was 0.60 (95% CI: 0.40-0.89) for all randomized 
women with no evidence of heterogeneity between studies (p=0.52 and I
2 
0.0%). In the first 2.5 
years of follow-up (prevalence screen) cancer detection did not differ significantly between the 
study arms (RR 0.79 (95% CI: 0.46-1.36) but was significantly lower in the intervention arm 
thereafter (RR 0.45 (95% CI: 0.25-0.81). Among women with a negative test at baseline, the 
rate ratios became more pronounced. Comparing HPV negative women in intervention arm to 
cytology negative women in the control arm, the rate ratio for cancer was 0.30 (95% CI: 0.15-
0.60), again with no heterogeneity between studies. As further confirmation, the random effects 
model showed similar results (RR 0.34 (95% CI: 0.14-0.86).   
In addition to the main results, we examined several sub-questions of interest. When 
looking at morphology, the effect for the overall study period was greater for adenocarcinoma 
than squamous cell carcinoma (RR 0.31 (95% CI: 0.14-0.69) and 0.78 (95% CI: 0.49-1.25), 
respectively). By age, the effects were greatest for women ages 30-34 (RR 0.36 (95% CI: 0.14-
0.94) and no reduction was seen for women below the age of 30. This suggests that HPV-based 
screening should be implemented for women ages 30 and above.  
Previous studies have suggested that HPV-based screening would allow for longer 
screening intervals that cytology-based screening. The cumulative detection rate (cumulative 
incidence) for invasive cervical cancer was 15.4 (7.9-27.0) per 10
5
 and 36.0 (23.2-53.5) per 10
5
 
for cytology negative women at 3.5 and 5.5 years after entry, respectively whereas for HPV-
negative women, it was 4.6 (1.1-12.1) per 10
5 
and 8.7 (3.3-18.6) per 10
5
, respectively (Figure 
4). The cumulative detection rate among HPV-negative women at 5.5 years was lower than for 
cytology negative women at 3.5 years implying that lengthened intervals with HPV-based 
screening would be possible.  
To our knowledge, this is the first analysis to focus on comparing efficacy of screening 
tests against invasive cervical cancer in regularly screened women and to address issues of age, 
cancer stage, and morphology. A cluster randomized trial in India compared once-in-a-lifetome 
screening with HPV to cytology, visual inspection, or no screening and found that one-time 
HPV screening resulted in a reduction of advanced cancers and death (124). In general, results 
of RCTs of cytology- versus HPV-based screening have been focused on precursor lesions and 
have had more limited follow-up (125, 126). A previous meta-analysis did not report 
cumulative incidence since recruitment which means that the observed decrease with HPV-
based screening could have been due to earlier detection (127). Our results show that HPV-
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based screening provides greater protection against cancer than cytology and that HPV-based 
screening should be implemented from age 30, extending intervals up to 5 years.  
 
Figure 4. Cumulative incidence of invasive cervical carcinoma 
 
*Observations are censored 2.5 years after CIN2 or CIN3 detection, if any 
7.2 STUDY II 
Of the 12,527 women recruited to Swedescreen, 12,091 had baseline cytology and at least 
one follow-up test. Over 13 years of follow-up, 387 women developed a histologically 
confirmed CIN2+ lesion (median follow-up time for the whole cohort was 10.95 years) and 230 
women developed a CIN3+ lesion (median follow-up time for the whole cohort was 10.98 
years). The cumulative incidence of CIN2+ among women negative for cytology at baseline in 
the control arm increased steadily over follow-up whereas the cumulative incidence increased 
slowly for HPV negative women with very little difference between HPV negative and double 
negative (cytology and HPV negative) women during follow-up (Figure 5).  
Patterns were similar for CIN3+; however, slightly more pronounced differences were 
seen between HPV-negative and double negative women after 7 years of follow-up, probably 
due to improvements in the testing method used in the control arm (Figure 6). At 11 years of 
follow-up, differences in the cumulative incidence of CIN2+ among cytology negative women 
at baseline in the intervention and control arms diminished, highlighting the earlier diagnosis 
potential with HPV-based testing and the apparent absence of overdiagnosis when viewing the 
data over the long-term. Again, similar patterns were observed when comparing cytology 
negative women in the intervention and control arms with the outcome of CIN3+. The 
cumulative incidences were somewhat different (higher in the intervention arm) until 7 years of 
follow-up.  
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Figure 5. Cumulative incidence of cervical intraepithelial neoplasia grade 2 or worse 
(CIN2+) over 13 years of follow-up by study arm and baseline test result (test result 
groups not mutually exclusive) 
 
 
 
 
Figure 6. Cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse 
(CIN3+) over 13 years of follow-up by study arm and baseline test result (test result 
groups not mutually exclusive) 
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An examination of the longitudinal test characteristics revealed that the sensitivity of 
cytology in the control arm at 3 years of follow-up was similar to that of HPV testing in the 
intervention arm at 5 years (85.94% (95% CI: 76.85-91.84) and 86.40% (95% CI: 79.21-91.37), 
respectively) with no statistically significant difference in proportions (p=0.8970). For CIN3+ 
the pattern of results remained the same, the sensitivity in control arm with cytology at 3 years 
was 92.02% (95% CI: 80.59-96.97) and in the intervention arm with HPV testing at 5 years it 
was 89.34% (95% CI: 80.10-94.58) with no significant difference in the proportions 
(p=0.4871). As expected with HPV-based testing, the specificity was lower than cytology at all 
time points but still above 94% for HPV testing and 90% for double testing when looking at 
CIN2+ as an outcome and above 90% for HPV testing and 85% for double testing with CIN3+ 
as an outcome.  
The drop in specificity for double testing and the minimal gain in sensitivity, suggests that 
double testing is not likely to offer a pragrammatically worthwhile improvement. Taken 
together, the results suggest that HPV testing could be used as a stand-alone test and that 
intervals could be safely extended compared to cytology. The increased detection with HPV 
based screening the first years of follow-up that has been observed in the first results of 
Swedescreen as well as other published trials (108, 126, 128), seems to decrease overtime and 
represent, instead, early detection.  
7.3 STUDY III 
Study III made use of the same long-term follow-up data from the Swedescreen trial as 
used in Studies I and II but the follow-up was further extended to December 2012 for all 
counties. In total, 11,683 women had complete baseline testing (HPV and cytology information) 
and at least 1 follow-up test were included.  The median follow-up time was 11.07 during which 
648 ASCUS, 334 LSIL, and 183 CIN1 cases were identified. Analyses were run with study 
arms separately and then combined and, in addition to the HR HPV types examined in the full 
cohort, non-HR HPV types were examined in the control arm where updated HPV testing was 
available. In the control arm, the absolute risk for ASCUS/LSIL was highest for non-HR HPV 
types 73, 53, 6, and 67.  The first screening round PAR for ASCUS, LSIL, and CIN1 separately 
by type is given in Figure 7 and can be helpful in understanding the proportion of disease that 
would be eliminated if the infection was prevented in the population. This is of particular 
interest as it gives us a sense of what we can expect from vaccines. PARs for ASCUS/LSIL 
were estimated for the bivalent, quadrivalent and 9-valent vaccine types. Given that low-grade 
lesions are increasing in incidence, these results bode well for reducing the overall burden of 
low-grade lesions through vaccination.  
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Figure 7. Population attributable proportion (PAR, %) by type for ASCUS, LSIL and CIN1 in 
the first 3 years of follow-up, study arms combined  
 
 
Overall, the IRRs for ASCUS/LSIL were highly follow-up time dependent with the IRR 
for infection with any HR type decreasing from 18.6 (95% CI: 14.9-23.4) in the first screening 
round during follow-up to 1.1 (95% CI: 0.7-1.8) in the fourth screening round. Similar 
decreases were seen when looking at the type-specific adjusted IRRs. It should be noted that we 
chose to adjust for multiple-type infections by entering all HR types separately into the model. 
We chose this approach to minimize assumptions and reduce bias. There is discussion in the 
field on how best to do this – some studies have taken a hierarchical approach to adjust for 
multiple-type infections while others have done it proportionally (129, 130). Both approaches 
can bias the results by overestimating the contribution of common oncogenic types (hierarchical 
approach) or overestimating the contribution of lesser oncogenic types (proportional approach). 
Given the biases apparent in these approaches and conflicting evidence in the field regarding 
interactions between types, we chose to adjust for multiple type infections by treating them as 
confounders.  
The results of Study III suggest that type-specific risks for ASCUS/LSIL differ and that 
most lesions are found during the first screening round. The differences in HPV testing between 
the intervention and control arms resulted in only a small increase in the proportion of low-
grade lesions caused by the types screened for, allowing us to pool the study arms. By 
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calculating both absolute as well as relative estimates of type-specific risk we hope that the 
results can be used to assist in healthcare planning by estimating patient burden and evaluate the 
magnitude of effect of specific types on development of ASCUS/LSIL.  
7.4 STUDIES IV AND V 
Out of 34 EU/EFTA countries that were sent a questionnaire, 29 countries responded to 
the sections related to cervical screening and 27 countries responded regarding vaccination 
efforts. Responses were received from professional organizations, researchers, registries, 
screening programs, departments of pathology, public health departments, ministries of health, 
and cancer societies, reflecting the range of actors involved with prevention activities. Data 
collection took 2 years as some countries required repeated contact before a response was 
elicited and responses varied in detail and supporting documentation.  
Details of program organization and systems for monitoring and evaluation are described 
in the tables of the manuscripts and provide an overview of the key data points gathered. 
Briefly, cervical screening was offered to women through an organized program in 20 countries 
and through a publicly mandated program in 21 countries. Quality assurance programs for 
screening were established in all but three countries and mass screening registries were in place 
in all but four countries with individual level data systematically collected in all but three 
countries. In reviewing the information submitted, it became apparent that each country has 
approached prevention activities from their own healthcare perspective. While some programs 
had similar characteristics such screening intervals and target populations, in general programs 
were integrated into existing systems and implemented according to healthcare tradition in that 
country. Therefore, the ability to separate costs was more challenging than anticipated. More 
established programs were able to more fully track screening program operations and provide 
more detailed responses to the questionnaire items.  
Guidelines regarding how HPV vaccination programs should be implemented are less 
well-developed and authoritative compared to screening recommendations. The majority of 
countries surveyed reported having an organized vaccination program with a centralized 
vaccination registry allowing for monitoring of key performance and impact indicators. 
Registration of vaccination is ideally coupled with the ability to link information to health 
outcomes to monitor the impact of vaccination in population and optimize prevention efforts. 
Six countries reported that they could perform data registry linkages. Among countries 
reporting an organized vaccination program, 46% reported using a school-based delivery 
strategy alone and 27% used a school-based strategy along with a secondary delivery strategy. 
Evidence from a recent meta-analysis suggests that programs that vaccinate girls at a young age 
and achieve a high-coverage, often through school-based delivery of the vaccine, achieve the 
greatest impact on HPV-related disease outcomes (131, 132). Continued monitoring and 
evaluation of vaccine impact in population will be needed with a comprehensive approach to 
ensuring that the program functions as it should and has the intended effect.   
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7.5 STUDY VI 
Three alternative vaccination scenarios were compared to the base-case (Strategy 1, the 
vaccination program as it currently is with routine vaccination of school-age girls and a catch-
up of 13-18 year old girls). The alternative scenarios included an extended one-time catch-up 
with high coverage up to age 26 among girls (Strategy 2), adding routine vaccination of school-
age boys to the extended catch-up of girls (Strategy 3), and then adding an extended one-time 
catch-up of boys up to 26 as well, in addition to routine vaccination of both genders and an 
extended one-time catch-up of girls (Strategy 4). This last option represented the most extensive 
potential expansion to the program. The outcome of interest in all the analyses was HPV 16/18 
prevalence among women ages 15-35 in the years following vaccination program start. By 
restricting to this age-range, we sought to capture the impact of vaccination in the age-range 
where HPV prevalence peaks and minimize the effect of different screening practices on the 
findings.  
When looking at the reduction of HPV prevalence attributable to vaccination (%RAV), 
the strategies including the extended catch-up of females accelerated the reduction in 
prevalence compared to the base case and increased the effectiveness. Including an extended 
catch-up of males further sped up the impact with the effects lasting for 25-30 years post-
vaccination program start (Figure 8). Overall, results were similar when evaluating RAV for the 
HPV types included in the 9-valent vaccine.  
 
Figure 8. Percent prevalence reduction attributable to vaccination (RAV) of  
HPV16/18 prevalence in women age 15-34 years 
 
For the first time, we evaluated HPV vaccination program resilience, or the ability of the 
program to maintain effectiveness despite threats to coverage levels. This was examined by 
halving the coverage for a period of 5 years and comparing the %RAV. If only girls were 
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vaccinated, the effectiveness decreased up to 3.1% whereas if boys were included in the 
vaccination program, either as routine vaccination or routine with an extended catch-up, the 
decrease in effectiveness was negligible (peak reduction was 0.43%) (Figure 9).  
 
Figure 9. Resilience of vaccination strategies to a 5-year impaired coverage 
Upper panel: extended catch-up among girls only 
Lower panel: extended catch-up among boys and girls 
 
 
The stability of a vaccination program is dependent upon healthcare politics including budgets 
and priorities and acceptance of the vaccine in the population. Dramatic decreases in coverage 
have been observed in other countries where faith in the vaccine dropped suddenly (133). Drops 
in effectiveness would have long-lasting effects, especially if there is a change in the 
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background infection rates as a result of changes in risk-taking behavior, migration in the 
population, or if screening programs change as a result of vaccination and can no longer 
accommodate unvaccinated or under-vaccinated cohorts.  
Instead of calculating cost-effectiveness of different strategies, we opted to compare the 
cumulative number of doses needed in Strategies 2, 3, and 4 to the base-case Strategy 1. The 
results are based on demographic projections and therefore aim to avoid pitfalls inherent in 
basing cost calculations on quickly changing vaccine prices. As expected, given the scope of the 
expanded catch-up strategies proposed, compared to the base-case, Strategies 2, 3, and 4 
required an increased number of doses, especially during the implementation of the catch-up. 
After 30 years, the ratio of cumulative number of doses used converged to 1 and 2 times the 
base-case for Strategies 2 and 3; however, it took nearly 50 years for Strategy 4 to converge to 2 
times the base-case. With declining vaccine prices, extending vaccination to more cohorts is 
attractive; programs will need to consider the increases in doses needed compared to existing 
efforts to be sure health budgets and systems will cope.  
7.6 METHODOLOGICAL CONSIDERATIONS 
We are not afraid to follow truth wherever it may lead, nor to tolerate any error so long as 
reason is left free to combat it.  
        -Thomas Jefferson 
 
There are a series of methodological considerations that warrant discussion. While we 
have tried to address the major issues in the articles themselves, some concepts deserve further 
attention.  
Misclassification is a type of measurement error and can be divided into differential, 
where the probability of being misclassified differs by group or category, and non-differential 
misclassification, where the probability of being misclassified is the same across groups or 
categories (50). In cervical screening, misclassification of disease outcomes occurs as a result of 
the screening (sample taking) or the laboratory interpretation (134). In studies II and III, there is 
a chance that the cytological and histopathological endpoints used could be misclassified. Most 
likely the misclassification would be non-differential as the outcomes were collected from the 
NKCx and diagnoses were determined in routine health care without knowledge of 
randomization group. To overcome this, all endpoints could have been re-reviewed. However, 
this was unfeasible in the current studies. Furthermore, if this had been carried out, the results 
would not be as directly representative of diagnoses found in the screening.  
An improvement to the original HPV test was used for the testing of frozen baseline 
samples in the control arm of Swedescreen (data used in Studies II and III). This improvement 
resulted in some increase in HR HPV prevalence in the control arm (9.3%) as compared to the 
intervention arm (7.3%).  However, in Study II we found that the increased sensitivity of the 
updated test did not result in a difference in longitudinal sensitivity until after 5 years of follow-
up. When the Swedescreen trial was designed, IARC classified 14 HPV types as high risk. 
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Since then, type 66 has been demoted and is no longer classified as oncogenic by IARC. For 
these analyses, we kept the original HR HPV types included at the beginning of the study. We 
present type-specific and adjusted measures allowing the readers to evaluate the risk evidence 
on type 66. It should be noted that we have chosen the term “non-HR HPV type” instead of 
“low-risk HPV type” as a more conservative approach to describing oncogenic potential. 
Definitively calling types “low-risk” is a potential misnomer as we have not concluded that they 
cannot cause cancer, only that it has not yet be definitively observed. 
The Swedescreen RCT trial did not systematically collect information on further 
background characteristics or behavior of the study participants. The study was randomized and 
women in the groups were found to be similar. Studies including behavioral risk factors are 
important for understanding risk factors for disease. However, the Swedescreen trial aimed to 
evaluate the impact of screening with different methods. There may come a time when 
screening is stratified more closely by individual risk profiles, such as vaccination status, but for 
the time being, the program seeks to target all women, regardless of sexual behavior history and 
STI diagnoses, smoking status, etc.  
The external validity of RCTs has been questioned as inclusion criteria for trials are often 
strict and study settings and protocols may not match real-life healthcare practice (135). 
Inclusion criteria for the European RCTs included in this thesis were simple and mainly related 
to characteristics that would have excluded women from routine screening anyway. Women 
were recruited from organized screening programs and are therefore representative of women 
attending screening; however, they may be different from women who do not routinely attend in 
terms of risk for cervical cancer.  
Heterogeneity between studies was a concern in Study I given somewhat different study 
designs and follow-up strategies. That said, study specific estimates of the effect of HPV 
screening compared to cytology screening were similar before pooling, suggesting that 
differences between studies did not have a major impact on the overall impact the results. Tests 
for heterogeneity revealed that there were no significant differences in the study materials and 
the random effects models gave similar results to the fixed effects models. There was 
heterogeneity detected when examining rate ratio for women who had a biopsy in the 
intervention and control arms; however, the heterogeneity between the remaining studies 
disappeared when NTCC was removed from the pooled estimates. 
The questionnaire circulated for Studies IV and V was designed early in my PhD career 
and was a first attempt at capturing detailed program information. After reviewing the data sent 
in by countries and through discussing the results and working through reviewers comments, 
there are several areas of improvement and a series of additional questions that could be added 
to further describe program nuances. The results presented in Studies IV and V serve as a 
baseline description of prevention efforts in Europe and the plan is to update and circulate the 
questionnaire at regular intervals so that changes to programs can be captured.  
Given the political nature of the survey, countries may have felt pressured to present 
progress towards implementing organized, quality-assured prevention programs in a more 
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positive light since international recommendations exist. The results may be impacted by some 
reporting bias, or under-reporting of issues that need to be improved. The language and 
terminology used in the survey was intended to mirror existing literature and guidelines but 
concepts could be defined differently across countries leading to variations in question 
interpretations. We did not explore prevention efforts in countries that reported not having an 
organized program. Perhaps screening and vaccination efforts in these countries should have 
been explored in more depth so that as healthcare systems further develop and adopt new 
policies, comparisons could have been made and impact of changes to screening practice more 
closely monitored.   
With regard to specific changes that could be addressed in subsequent rounds of the 
survey to better capture screening information, additional information on how organized 
programs track tests taken outside the program would have been useful. For example, what 
proportion of tests taken outside the program could be classified as over-screening and how do 
programs calculate the proportion of tests taken outside the program? Individual invitations to 
screening are known to have an effect on coverage but invitations systems are reliant on up-to-
date and accurate information on the target population. More information on the status of 
personal data laws would have been helpful to provide context for invitations and data 
collection possibilities. Furthermore, for programs that can integrate opportunistic and 
organized tests, we could have asked more systematically whether organized test invitations are 
delayed as result of an opportunistic test and how exclusion criteria for invitations are verified 
(e.g. hysterectomies). We asked if staff responsibilities were defined within the screening 
program but we did not go on to ask more specific questions about individual responsibilities of 
program actors. This could be included in the next round of the survey. Collecting information 
on costs was challenging as healthcare systems are country-specific and, depending on 
integration of screening in health care, direct medical costs may be difficult to tease out from 
other services. That said, more information on where financing comes from for different parts of 
the screening process could have been interesting. As more countries implement primary HPV-
based screening, questions will need to be added to capture the specifics of HPV screening 
organization and QA.  
The survey did not fully address issues of QA in vaccination programs. To better describe 
QA in vaccination programs, further questions could have been asked about the vaccine cold 
chain, vaccine delivery systems, timing of the vaccine schedule, and follow-up of vaccine safety 
issues including vaccine administration. The information collected pertains more to the overall 
monitoring and evaluation of vaccination programs and whether there is a link between 
vaccination and screening. We asked countries to submit information on how they calculated 
vaccination coverage including how they accounted for schedules that extended over reporting 
periods and receipt of doses outside the recommended schedule. In the next iteration of the 
survey, the connection between vaccination delivery strategy and impact in population could be 
further investigated and more specific information on coverage trends and compliance to dosing 
schedules could be collected.  
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For the model, we decided to focus on the HPV types in the current vaccines, modeling 
the 9-valent results in the additional analyses. Cross-protection of the vaccines was not 
modelled given uncertainties in the long-term duration of the cross protection (136). We also 
did not look at outcomes among men as the natural history of infections in men is less well-
defined. There has been a significant movement towards modeling the cost-effectiveness of 
HPV vaccination; however, outcomes and cost modeling approaches differ (137, 138) and input 
healthcare and vaccine costs change. We chose to focus on a ratio measure of the cumulative 
number of doses where each alternative vaccination strategy was compared to the base case.  
In contrast to non-communicable diseases, when dealing with a communicable disease, 
intervening to prevent infection or disease in some will have repercussions for others (139). 
Dynamic transmission models are well-suited for capturing the impact of HPV vaccination as 
they allow for infection risk to change over time as a result of herd protection. HPV-related 
outcomes have been modeled using a natural history approach as well. In this case, model 
compartments represent different health states and movement between the states is based on a 
probability (140). The choice of modeling technique in Study VI reflects the desire to represent 
HPV as a communicable infection and to account for indirect effects of prevention strategies. 
Other modeling approaches may also be valid. As the number of HPV models increase, 
comparing results becomes increasingly difficult as structures and assumptions differ. This has 
an impact on the likelihood that model results will be translated into public health practice as 
tradeoffs might not be clear or applicable across settings. There is an international group of 
modelers working to standardize HPV model reporting by developing a framework similar to 
the CONSORT guidelines which bodes well for continued transparency and quality.  
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8 CONCLUSIONS 
Studies I, II, and III 
 Compared to screening with cytology, HPV-based screening provides 60-70% greater 
protection against invasive cervical cancer, although differences by histological type 
were found.  
 HPV-based screening can effectively start at age 30, and screening intervals can be 
lengthened to at least 5 years. 
 The longitudinal sensitivity of cytology for high grade lesions at 3 years of follow-up 
was similar to the sensitivity of HPV testing at 5 years of follow-up. 
 The cumulative incidence of high grade lesions was the same for HPV- and cytology 
screening, implying that the increased sensitivity of HPV screening reflects early 
diagnosis rather than overdiagnosis. 
 The type-specific IRRs for ASCUS/LSIL were high in the first screening round but 
decreased over subsequent screening rounds. 
 HPV type 16 contributed to the greatest proportion of ASCUS, LSIL, and CIN1 risk 
in the population.  
 Most ASCUS/LSIL lesions are caused by new HPV infections and lesions are most 
often found in the first screening round.  
Studies IV and V 
 Organized efforts for QA, monitoring, and evaluation in cervical screening were 
carried out to a differing extent and were not standardized, making it difficult to 
compare prevention efforts.  
 Most countries found it hard to estimate the costs associated with launching and 
operating the screening organized program. 
 The majority of European countries had some level of HPV vaccination activity; 
however, organization and quality differed across countries.  
 Centralized vaccine registries were in place in the majority of countries with an 
organized program, allowing for monitoring of key indicators but level detail varied. 
 Costs of organization and monitoring were difficult to estimate and varied 
significantly.  
 Further development of this survey tool could support ongoing evaluation of 
prevention program development.  
Study VI 
 Extending vaccination catch-up of women and men would further reduce HPV 
prevalence in women, achieving results earlier than female-only routine vaccination 
 The resilience of vaccination programs is improved by including males in the 
vaccination program.
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9 IMPLICATIONS AND FUTURE DIRECTIONS 
Evidence has amassed from randomized controlled trials comparing HPV- and 
cytology-based screening demonstrating that HPV-testing is effective as a primary screening 
tool.  The movement towards primary HPV-based screening has now begun. A pilot study is 
on-going in the context of the Stockholm County organized screening program where women 
have been randomized 1:1 to HPV- or cytology-based testing. The pilot program will be 
complete before Sweden as a whole moves to HPV-based screening in 2017. A pilot program 
to evaluate HPV-based screening in population is also on-going in England and in the 
Netherlands, a decision was made to switch to HPV-based testing for the screening program 
in 2016. The results of Studies I and II imply that intervals for HPV-based screening could be 
lengthened. However, actual intervals for proposed HPV-based screening schemes differ – in 
Sweden the proposal includes 3 and 7 year intervals for younger and older age groups, 
respectively, and in the Netherlands 10-year intervals will be used. Switches in testing 
method will need to be monitored and evaluated. Most likely, additional adjustments will 
need to be made to incrementally optimize new strategies.  
The EU guidelines from 2008 recommended that HPV testing as a primary screening 
method should be used only in pilot programs (53). Updated cervical cancer screening 
guidelines are due to be released shortly. As preliminarily released at the EUROGIN 
International Congress in Spain this past February, the updated guidelines will recommend 
that primary HPV-based screening can be implemented context of an organized, population-
based screening programs with developed guidelines for triage, referral, and follow-up testing 
of positive women. Co-testing with cytology will be discouraged, in-line with our results 
from Study II. The updated guidelines will recommend the use of cytology as triage and 
caution against referring all HPV-positive women to colposcopy. Programs will need to 
budget time for counselling HPV-positive women as HPV-test results can carry different 
implications than cytology and raise questions regarding STIs, transmission, and management 
strategies.  
Organized prevention efforts are favored as they provide a structure for monitoring and 
evaluating program efforts and can ensure more equitable access to care and resources. In 
Studies IV and V, we mapped and tried to examine nuances in prevention efforts in order to 
better understand country-specific health systems and, over time, guide changes that need to 
be made to strengthen guidelines and prevention efforts. In the next iteration of the survey, 
greater focus will need to be placed on gathering information regarding shifts in testing 
methods and screening guidelines for vaccinated populations. Changes will occur rapidly 
once the updated guidelines are released so recirculating the survey would be advantageous to 
capture policy shifts and impact.  
Since the introduction of the HPV vaccination into routine vaccination programs, the 
target gender of vaccination has been intensely debated. In Study VI, we show that extending 
vaccination catch-up among girls and including boys in vaccination programs anticipates 
reductions in prevalence among girls, achieving results earlier, and strengthens the resilience 
of programs.  The resilience of vaccination programs is of particular concern in settings 
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where healthcare stability cannot be guaranteed. Fluctuations in vaccination coverage appear 
to have a long-lasting impact on program effectiveness. When we modelled a complete 
interruption of vaccination, the effectiveness of girls-only vaccination against vaccine-type 
HPV prevalence dropped significantly compared to when both girls and boys were 
vaccinated. Gender neutral vaccination could be considered as a tool to ensure that temporary 
coverage issues cannot threaten prevention efforts but settings that could benefit the most 
from extending vaccination may have the greatest challenges in securing consistent funding 
for vaccines.  
While the effectiveness of the HPV vaccine decreases with increasing age at 
vaccination, older girls and women may still benefit from vaccination (83). Vaccination up to 
26 is covered by Stockholm County, and with this in mind, we are working to organize a 
catch-up of girls between the ages of 19 and 26 in the hopes of increasing coverage in this 
older age group. This will also allow us to evaluate the performance of screening post-
vaccination. By vaccinating older girls and screening with HPV testing, the infections we 
detect will most likely be persistent infections, increasing the predictive value of HPV testing 
in younger women.  
Vaccine efficacy in males has be demonstrated in trials (141, 142) and some countries – 
Austria, Australian, and the United States – have started to encourage male vaccination (94, 
95). Implementing HPV vaccination of boys would require at least doubling the number of 
doses currently used, and more if extended catch-up programs were also included. Issues of 
ethics also come into play when considering the target gender of HPV vaccination – is it 
ethical to require that females bear the burden of vaccination when HPV infection effects and 
can be transmitted by both genders? Taking a broader perspective, are we missing potentially 
high-risk populations that will not benefit from herd effect generated by female-only 
vaccination? Evidence suggests that rates of anal cancer are high among men who have sex 
with men (MSM) (143) but female-only vaccination programs will not benefit MSM (144) 
and pockets of unvaccinated populations could be reservoirs for infection (145).  As costs for 
the vaccines decrease and awareness of HPV and HPV-related diseases increases, hopefully 
the choice between which gender(s) to vaccinate will become less controversial.  
HPV DNA testing can be implemented as a self-test and has been shown to increase 
screening uptake among non-attenders to screening (146). While evidence suggests that 
clinician-collected samples have better sensitivity than self-collected samples, using a PCR-
based HPV test can improve the relative sensitivity and specificity of self-collected samples 
(147). Rapid HPV tests, such as careHPV, have recently been evaluated in resource-poor 
settings and promise better sensitivity than cytology and visual inspection methods which 
rely on more subjective evaluation of samples (148).  With an increasing number of tests 
available on the market and progressively more complex screening and triage algorithms, the 
search for the appropriate use of biomarkers in determining risk has become an area of 
growing attention.  Specifically, an area of particular interest is the possibility of stratifying 
HPV positive women by risk for progression to lesions using biomarkers of gene over 
expression (149). If these biomarkers prove to be effective, then a new age of even more 
individualized, tailored screening is possible. A balance would have to be found that allows 
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for a logistically viable generalized implementation and meaningful, individualized risk 
stratification. Programs must be able to maintain high coverage and must further develop out-
reach to long-term non-attenders.  
For many years to come, we will have non-vaccinated cohorts, partially vaccinated 
cohorts, and vaccinated cohorts all participating in screening with varying degrees of risk for 
cancer. Next generation vaccines, such as the 9-valent vaccine protecting against HPV types 
6, 11, 16, 18, 31, 33, 45, 52, and 58, promise extended protection against cervical cancer (80).  
As the first cohorts of women vaccinated enter screening ages, screening programs will need 
to adjust, especially with the prospect of vaccines that include an increasing number of types. 
The decrease in cancer risk in the population after mass-vaccination and the decrease in 
CIN2+ risk in HPV-positive women will lead to a different trade-offs between screening 
efforts and benefits. The intersection of vaccination and screening efforts needs to be 
modelled and evaluated so that we make the most efficient use of healthcare resources and 
testing methods while promoting the health of our populations (150). 
As we move from trial evidence to practice, focusing our energy on evaluating 
prevention strategies in population using a comparative effectiveness research (CER) design, 
also known as randomized health services (RHS) trials could help to inform the broader roll-
out of new policies. Evidence from randomized controlled trials have provided strong 
efficacy results HPV vaccines and screening methods. The next step is to implement new, 
proven prevention strategies through the routine health service infrastructure. RHS trials are 
designed to implement new strategies in a randomized fashion in order to reduce potential for 
bias and ensure that the outcomes evaluated are temporally comparable (151). Such trials can 
help us understand whether the new intervention is cost-effective, has the effect anticipated, 
is accepted in population, and whether the health system infrastructure can adapt to new 
policies and procedures (151).  In a RHS design, costs of the new intervention and related 
services are carried by the health system itself or whatever local routine is applicable 
(ministry of health, individual-payer etc) but the results are analyzed in a research setting and 
the study is submitted for ethical review.  
Rolling out new interventions with monitoring and incremental revision allows for 
evidence-based improvement of prevention programs and connects healthcare practice to 
research. In my experience, the RHS design lends itself to close collaboration between 
researchers and program officers. Time, effort, and resources can be concentrated on 
sequential optimization instead of rigid sweeping changes that may not align fully with actual 
prevention program logistics and may take too long to develop and implement for 
populations in need.  
This thesis has focused on the optimization of cervical cancer efforts in Sweden and the 
rest of Europe. At the end of the day, Swedish and European women have benefitted 
tremendously from screening and vaccination. Cervical cancer incidence and mortality have 
decreased significantly since the implementation of screening and efforts to organize 
screening and implement HPV vaccination are on-going in most countries. Worldwide, there 
are approximately 528,000 new cases of cervical cancer each year and 266,000 deaths due to 
cervical cancer each year, 87% of which occur in resource-poor settings (152).  Given the 
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pressing burden to healthcare systems in the world’s poorest countries for treatment of 
disease, disease prevention efforts cannot always be prioritized. In our efforts to strengthen 
prevention efforts here at home, we must not forget our sisters in other, less fortunate settings. 
We must push ourselves to consider the implications of our findings in a variety of settings 
and continuously lead by example with evidence-based healthcare decision-making. We are 
fortunate to have a healthcare system and databases to monitor and evaluate healthcare 
practices and, therefore, I believe that we have a certain obligation to lead in seeking answers 
to some of the remaining questions. 
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12.1 EUROPEAN UNION SURVEY ON ORGANIZATION AND QUALITY 
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